

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
WO 02/06534 A2

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68
- (21) International Application Number: PCT/US01/22492
- (22) International Filing Date: 17 July 2001 (17.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/218,740 17 July 2000 (17.07.2000) US  
60/220,133 21 July 2000 (21.07.2000) US
- (71) Applicants: VANDERBILT UNIVERSITY [US/US]; 305 Kirkland Hall, Nashville, TN 37240 (US). CHIL-DREN'S HOSPITAL MEDICAL CENTER [US/US]; 3333 Burnet Avenue, Cincinnati, OH 45229 (US). ADVANCED RESEARCH AND TECHNOLOGY IN-STITUTE [US/US]; Indiana University, 1100 Waterway Boulevard, Indianapolis, IN 46202 (US). UNIVERSITY OF LEICESTER [GB/GB]; University Road, Leicester LE1 7RH (GB).
- (72) Inventors: LOYD, James, E.; 4111 Sneed Road, Nashville, TN 37215 (US). LANE, Kirk, B.; 8218 Twin Springs Court, Brentwood, TN 37027 (US). PHILLIPS, John, A., III; 5315 Lancelot Road, Brentwood, TN 37027 (US). NICHOLS, William, C.; 100 Woodridge Court, Loveland, OH 45140 (US). PAUCIULO, Michael, W.; 9512 Raven Lane, Blue Ash, OH 45242 (US). FOROUD, Tatiana; 5334 N. Pennsylvania Street, Indianapolis, IN 46220 (US). TREMBATH, Richard, C.; Hill Close Farm, Mainstreet, Owston, Oakham, Rutland LE15 8DH (GB). MACHADO, Rajiv, D.; Flat 53, Goscote House, Sparkenhoe Street, Leicester LE2 0TL (GB). THOMSON, Jennifer, R.; 41 Flax House, Navigation Walk, Leeds LS10 1JH (GB).
- (74) Agents: SPRATT, Gwendolyn, D. et al.; Needle & Rosenberg, P.C., Suite 1200, The Candler Building, 127 Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF DIAGNOSING PULMONARY HYPERTENSION

(57) Abstract: This invention relates generally to a method of identifying an individual having an increased susceptibility to developing Familial Primary Pulmonary Hypertension (FPPH), as well as to a method for diagnosing an individual suffering from FPPH. The invention also relates to a method of identifying an individual having an increased susceptibility to developing (non-familial) Primary Pulmonary Hypertension (PPH), as well as to a method for diagnosing an individual suffering from PPH.

## METHOD OF DIAGNOSING PULMONARY HYPERTENSION

### FIELD OF THE INVENTION

This invention relates generally to a method of identifying an individual having an increased susceptibility to developing Familial Primary Pulmonary Hypertension (FPPH), as well as to a method for diagnosing an individual suffering from FPPH. The invention also relates to a method of identifying an individual having an increased susceptibility to developing non-familial, or sporadic, Primary Pulmonary Hypertension (PPH), as well as to a method for diagnosing an individual suffering from sporadic PPH. The invention also relates to a method of identifying an agent capable of altering the symptoms of PPH in an individual suffering from familial or sporadic PPH, comprising contacting a test agent with Bone Morphogenic Protein Receptor II (BMPR-II) and determining whether the test agent alters BMPR-II activity, wherein an alteration in BMPR-II activity in the presence of the test agent as compared with BMPR-II activity in the absence of the test agent indicates that the test agent is capable of altering the symptoms of PPH in an individual suffering from familial or sporadic PPH.

### BACKGROUND OF THE INVENTION

Primary pulmonary hypertension (PPH) is characterized by sustained elevation of pulmonary artery pressure (greater than 25 mmHg at rest and greater than 30 mmHg during exercise) and with no identifiable cause, such as recurrent thromboembolism, chronic hypoxic lung disease or left-sided cardiac disease. PPH is twice as common in females than males and symptoms develop typically in the 3<sup>rd</sup> and 4<sup>th</sup> decades of life, although the disease may occur at any age. Despite advances in therapy, mortality in PPH remains high with mean survival from onset of disease only 2.5 year.

At least 6 % of individuals diagnosed with PPH have a known family history of the disorder. The disease can be classified as being either familial (more than one affected relative has been identified in at least 6% of cases (familial PPH; MIM 178600) (ref. 3)) or sporadic. Familial PPH (FPPH) segregates as an autosomal dominant disorder, with markedly reduced penetrance.

There is a need to identify the genetic basis for this devastating disease in order to better diagnose and treat patients suffering from PPH.

### BRIEF SUMMARY OF THE INVENTION

The invention relates to a method of identifying a subject having an increased susceptibility for developing pulmonary hypertension, comprising detecting a mutant Bone Morphogenic Protein Receptor II (BMPR-II) polypeptide or a mutated Bone Morphogenic Protein Receptor 2 (BMPR2) nucleic acid in the subject, thereby  
5 identifying a subject having an increased susceptibility for developing pulmonary hypertension. Wild-type BMPR2 nucleotide sequence is SEQ ID NO:1. Wild-type BMPR-II amino acid sequence is SEQ ID NO:2.

In one aspect, the mutated BMPR2 nucleic acid or mutant BMPR-II polypeptide  
10 has a sequence associated with pulmonary hypertension.

In another aspect, the mutated BMPR2 nucleic acid comprises a missense mutation.

In yet another aspect, the mutated BMPR2 nucleic acid comprises a nonsense mutation.

15 In another aspect, the mutated BMPR2 nucleic acid comprises a deletion mutation.

In another aspect, the mutated BMPR2 nucleic acid comprises an insertion mutation.

In another aspect, the mutated BMPR2 nucleic acid comprises a truncation  
20 mutation. Preferably, the mutated BMPR2 nucleic acid is truncated at a nucleotide position of the sequence set forth in SEQ ID NO:1 which is 3' to nucleotide position 2695.

In another aspect, the subject having an increased susceptibility for developing pulmonary hypertension is identified by detecting a BMPR2 nucleic acid having a  
25 sequence associated with pulmonary hypertension.

In a preferred aspect, the pulmonary hypertension is primary pulmonary hypertension. In another aspect, the pulmonary hypertension is secondary pulmonary hypertension.

In various preferred embodiments, the mutated BMPR2 nucleic acid can include  
30 a missense mutation or a nonsense mutation.

In another aspect, the invention features a method of identifying a mutant BMPR-II polypeptide or a mutated BMPR2 nucleic acid, including detecting, in a patient with PPH, a BMPR-II polypeptide that is not present in normal subjects or a BMPR2 nucleic acid that is not present in normal subjects, thereby identifying a mutant  
5 BMPR-II polypeptide or a mutated BMPR2 nucleic acid.

In another aspect, the invention features a method of increasing BMPR-II biological activity.

In another aspect, the invention features a method of decreasing BMPR-II biological activity.

10 In another aspect, the invention features a method of identifying a compound that modulates the biological activity of a BMPR-II polypeptide, including: a) contacting a sample including a BMPR-II polypeptide or a BMPR2 nucleic acid with the compound; and b) measuring BMPR-II biological activity in the sample, whereby an increase or decrease in BMPR-II biological activity, compared to BMPR-II  
15 biological activity in an identical sample not contacted with the compound, identifies a compound that modulates the biological activity of the BMPR-II polypeptide.

In various embodiments of this aspect of the invention, BMPR-II biological activity is increased or decreased; the BMPR-II polypeptide is a wild-type BMPR-II polypeptide or the BMPR2 nucleic acid is a wild-type BMPR2 nucleic acid; the  
20 BMPR-II polypeptide is a polymorphic variant of a BMPR-II polypeptide or the BMPR2 nucleic acid is a polymorphic variant of a BMPR2 nucleic acid; or the BMPR-II polypeptide is a mutant BMPR-II polypeptide or the BMPR2 nucleic acid is a mutated BMPR2 nucleic acid.

In another aspect, the invention features a non-human mammal having a  
25 deleted, mutated, or polymorphic variant BMPR2 gene. In various aspects of the twelfth aspect of the invention, the non-human mammal is a mouse; and/or the non-human mammal is homozygous for the deleted, mutated, or polymorphic variant BMPR2 gene.

Additional advantages of the invention will be set forth in part in the description  
30 which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained

by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

5

### BRIEF DESCRIPTION OF THE DRAWING

Figures 1A-1C are diagrams showing the physical map of the PPH1 interval at 2q33. Figure 1A shows the position of microsatellite markers. The markers are, from left to right, D2S115, D2S348, D2S2392, D2S2396, D2S1367, D2S116, D2S309, D2S2309, D2S2214, D2S2217, D2S346, D2S2289, 19E07, D2S307, CTLA4, D2S72, D2S105, D2S2189, D2S1384. Figure 1B shows the physical map contig (BAC/PAC) of the region surrounding BMPR2 including other genes analysed in the examples (12). Figure 1C shows the BMPR2 genomic structure, determined by analysis of available sequence data for BAC clone RP11-345N12 as well as sequence analysis of additional BAC clones identified by library screening as shown (not to scale).

15

Figure 2A is a diagram of the structure of BMPR2 cDNA. The location of the exons are indicated by the nucleotide start position in the cDNA. The cysteine residues within the extracellular domain are each denoted by \*. The filled in box represents the transmembrane domain and the stippled area identifies the region encoding the receptor kinase domain.

20

Figure 2B is a diagram of BLAST homology results showing protein similarity of human BMPR-II with receptors in other species and human TGF- $\beta$  receptor type II (TGFBR-II). Amino acid positions are shown together with the codon substitutions of conserved amino acids (boxed).

25

Figure 3 is a diagram of a basic function of BMPR-II. Two BMP type I receptors (BMPRIA and BMPRIB) and a single BMP type II receptor have been identified in mammals as serine/threonine kinase receptors. Following ligand binding to BMPR-II, this receptor forms a heteromeric complex with a type I receptor, resulting in activation of the type I receptor kinase domain which initiates phosphorylation of cytoplasmic signalling proteins, termed Smads, responsible for signal transduction.

## DETAILED DESCRIPTION OF THE INVENTION

The invention relates to the surprising discovery that FPPH is caused by mutations in the gene encoding a TGF- $\beta$  type II receptor, BMPR-II. The invention provides a method of identifying a subject having an increased susceptibility for developing pulmonary hypertension, comprising detecting a mutant Bone Morphogenic Protein Receptor II (BMPR-II) polypeptide or a mutated BMPR2 nucleic acid in the subject, thereby identifying a subject having an increased susceptibility for developing pulmonary hypertension. BMPR2 refers to the gene (or other nucleic acid) encoding a BMPR-II polypeptide. BMPR-II refers to the polypeptide encoded by a BMPR2 gene. Both of these terms are used herein as general identifiers. Thus, for example, a BMPR2 gene or nucleic acid refers to any gene or nucleic acid identified with or derived from a wild-type BMPR2 gene. For example, a mutant BMPR2 gene is a form of BMPR2 gene.

In a preferred embodiment, the pulmonary hypertension is primary pulmonary hypertension. In another embodiment, the pulmonary hypertension is secondary pulmonary hypertension.

As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, "a molecule" can mean a single molecule or more than one molecule.

By "about" is meant  $\pm 10\%$  of a recited value.

By "BMPR-II biological activity" is meant any physiological function attributable to a BMPR-II polypeptide molecule, including signal transduction. BMPR-II biological activity, as referred to herein, is relative to that of the normal BMPR-II polypeptide molecule. It may be desirable to increase or decrease BMPR-II biological activity.

Mechanisms by which a compound may increase BMPR-II biological activity include, but are not limited to, mimicry of endogenous BMPR-II polypeptide activity; stimulation of the activity of a less active or inactive version (for example, a mutant) of the BMPR-II polypeptide; or increasing the amount of BMPR-II polypeptide in a cell

(for example, by stimulating BMPR2 transcription and/or translation or by inhibiting BMPR2 mRNA or polypeptide degradation).

5 BMPR-II biological activity in a sample, such as a cell, tissue, or animal, may be indirectly measured by measuring the relative amount of BMPR2 mRNA (for example, by reverse transcription-polymerase chain reaction (RT-PCR) amplification, ribonuclease protection assay or Northern hybridization); the level of BMPR-II polypeptide (for example, by ELISA or Western blotting); or the activity of a reporter gene under the transcriptional regulation of a BMPR2 transcriptional regulatory region (by reporter gene assay, for example, employing beta-galactosidase, chloramphenicol acetyltransferase (CAT), luciferase, or green fluorescent protein, as is well known in  
10 the art). For example, a compound that increases the amount of wild-type BMPR-II polypeptide (or any other version of the polypeptide that maintains at least some activity) in a cell is a compound that increases biological activity of BMPR-II.

By "BMPR-II polypeptide" is meant a polypeptide that has, or is related to, the amino acid sequence of SEQ ID NO:2. A BMPR-II polypeptide contains an amino  
15 acid sequence that bears at least 80% sequence identity, preferably at least 85% sequence identity, more preferably at least 90% sequence identity, and most preferably at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:2.

20 By "wild-type BMPR-II polypeptide" is meant a BMPR-II polypeptide that has the amino acid sequence of SEQ ID NO:2.

By "wild-type BMPR2 nucleic acid" is meant a nucleic acid that encodes a wild-type BMPR-II polypeptide. An example of a wild-type BMPR2 nucleic acid is SEQ ID NO:1. Other wild-type BMPR2 nucleic acids include those containing introns,  
25 such as genomic BMPR2 nucleic acid.

By "polymorphic variant of a BMPR-II polypeptide" is meant a BMPR-II polypeptide containing an amino acid change, relative to wild-type, that does not result in an increase susceptibility to PPH. Such polymorphic amino acid variations in BMPR-II are seen in both PPH patients and in normal individuals.

30 By "mutant BMPR-II polypeptide" is meant a BMPR-II polypeptide having an amino acid sequence that differs from the sequence of a wild-type BMPR-II

polypeptide. One example of a wild-type BMPR-II polypeptide is a polypeptide having the amino acid sequence set forth in SEQ ID NO:2.

By "mutated BMPR2 nucleic acid" is meant a nucleic acid having a nucleotide sequence that differs from the sequence of the wild-type BMPR2 nucleic acid. One  
5 example of a wild-type BMPR2 nucleic acid is a nucleic acid having the nucleotide sequence set forth in SEQ ID NO:1. A "mutated nucleic acid" is also a nucleic acid that encodes a BMPR-II polypeptide having an amino acid sequence that differs from the sequence of a wild-type BMPR2 polypeptide. One example of a wild-type BMPR-II polypeptide is a polypeptide having the amino acid sequence set forth in SEQ ID  
10 NO:2. A mutated nucleic acid also includes a nucleic acid having a mutation (relative to the wild-type nucleic acid) in noncoding sequences, such as 5' or 3' sequences or intronic sequences.

By "increased susceptibility for developing pulmonary hypertension" is meant a subject who has a greater than normal chance of developing pulmonary hypertension,  
15 compared to the general population. Such subjects include, for example, a subject that harbors a mutation in a BMPR2 gene such that biological activity of BMPR-II is altered.

By "test compound" is meant a molecule, be it naturally occurring or artificially derived, that is surveyed for its ability to modulate BMPR-II activity. Test compounds  
20 may include, for example, peptides, polypeptides, synthesized organic molecules, naturally occurring organic molecules, nucleic acid molecules, and components thereof.

By "sample" is meant an animal; a tissue or organ from an animal; a cell (either within a subject, taken directly from a subject, or a cell maintained in culture or from a cultured cell line); a cell lysate (or lysate fraction) or cell extract; or a solution  
25 containing one or more molecules derived from a cell or cellular material (e.g. a polypeptide or nucleic acid), which is assayed as described herein. A sample may also be any body fluid or excretion (for example, but not limited to, blood, urine, stool, saliva, tears, bile) that contains cells or cell components.

By "modulate" is meant to alter, by increase or decrease.

30 By "normal subject" is meant an individual who does not have an increased susceptibility for developing pulmonary hypertension.

By an "effective amount" of a compound as provided herein is meant a sufficient amount of the compound to provide the desired effect. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of disease (or underlying genetic defect) that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.

By "isolated polypeptide" or "purified polypeptide" is meant a polypeptide (or a fragment thereof) that is substantially free from the materials with which the polypeptide is normally associated in nature. The polypeptides of the invention, or fragments thereof, can be obtained, for example, by extraction from a natural source (for example, a mammalian cell), by expression of a recombinant nucleic acid encoding the polypeptide (for example, in a cell or in a cell-free translation system), or by chemically synthesizing the polypeptide. In addition, polypeptide fragments may be obtained by any of these methods, or by cleaving full length polypeptides.

By "isolated nucleic acid" or "purified nucleic acid" is meant DNA that is free of the genes that, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, such as an autonomously replicating plasmid or virus; or incorporated into the genomic DNA of a prokaryote or eukaryote (e.g., a transgene); or which exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR, restriction endonuclease digestion, or chemical or *in vitro* synthesis). It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. The term "isolated nucleic acid" also refers to RNA, e.g., an mRNA molecule that is encoded by an isolated DNA molecule, or that is chemically synthesized, or that is separated or substantially free from at least some cellular components, for example, other types of RNA molecules or polypeptide molecules.

By a "transgene" is meant a nucleic acid sequence that is inserted by artifice into a cell and becomes a part of the genome of that cell and its progeny. Such a

transgene may be (but is not necessarily) partly or entirely heterologous (for example, derived from a different species) to the cell.

By "transgenic animal" an animal comprising a transgene as described above. Transgenic animals are made by techniques that are well known in the art.

5 By "knockout mutation" is meant an alteration in the nucleic acid sequence that reduces the biological activity of the polypeptide normally encoded therefrom by at least 80% relative to the unmutated gene. The mutation may, without limitation, be an insertion, deletion, frameshift, or missense mutation. A "knockout animal," for example, a knockout mouse, is an animal containing a knockout mutation. The  
10 knockout animal may be heterozygous or homozygous for the knockout mutation. Such knockout animals are generated by techniques that are well known in the art. A preferred form of knockout mutation is one where the biological activity of the BMPR-II polypeptide is not completely eliminated.

By "treat" is meant to administer a compound or molecule of the invention to a  
15 subject, such as a human or other mammal (for example, an animal model), that has an increased susceptibility for developing pulmonary hypertension, or that has pulmonary hypertension, in order to prevent or delay a worsening of the effects of the disease or condition, or to partially or fully reverse the effects of the disease.

By "prevent" is meant to minimize the chance that a subject who has an  
20 increased susceptibility for developing pulmonary hypertension will develop pulmonary hypertension.

By "specifically binds" is meant that an antibody recognizes and physically interacts with its cognate antigen (for example, a BMPR-II polypeptide) and does not significantly recognize and interact with other antigens; such an antibody may be a  
25 polyclonal antibody or a monoclonal antibody, which are generated by techniques that are well known in the art.

By "probe," "primer," or oligonucleotide is meant a single-stranded DNA or RNA molecule of defined sequence that can base-pair to a second DNA or RNA molecule that contains a complementary sequence (the "target"). The stability of the  
30 resulting hybrid depends upon the extent of the base-pairing that occurs. The extent of base-pairing is affected by parameters such as the degree of complementarity between

the probe and target molecules and the degree of stringency of the hybridization conditions. The degree of hybridization stringency is affected by parameters such as temperature, salt concentration, and the concentration of organic molecules such as formamide, and is determined by methods known to one skilled in the art. Probes or  
5 primers specific for BMPR2 nucleic acids (for example, genes and/or mRNAs) have at least 80%-90% sequence complementarity, preferably at least 91%-95% sequence complementarity, more preferably at least 96%-99% sequence complementarity, and most preferably 100% sequence complementarity to the region of the BMPR2 nucleic acid to which they hybridize. Probes, primers, and oligonucleotides may be detectably-  
10 labeled, either radioactively, or non-radioactively, by methods well-known to those skilled in the art. Probes, primers, and oligonucleotides are used for methods involving nucleic acid hybridization, such as: nucleic acid sequencing, reverse transcription and/or nucleic acid amplification by the polymerase chain reaction, single stranded conformational polymorphism (SSCP) analysis, restriction fragment polymorphism  
15 (RFLP) analysis, Southern hybridization, Northern hybridization, *in situ* hybridization, electrophoretic mobility shift assay (EMSA).

By "specifically hybridizes" is meant that a probe, primer, or oligonucleotide recognizes and physically interacts (that is, base-pairs) with a substantially complementary nucleic acid (for example, a BMPR2 nucleic acid) under high  
20 stringency conditions, and does not substantially base pair with other nucleic acids.

By "high stringency conditions" is meant conditions that allow hybridization comparable with that resulting from the use of a DNA probe of at least 40 nucleotides in length, in a buffer containing 0.5 M NaHPO<sub>4</sub>, pH 7.2, 7% SDS, 1 mM EDTA, and 1% BSA (Fraction V), at a temperature of 65°C, or a buffer containing 48% formamide,  
25 4.8X SSC, 0.2 M Tris-Cl, pH 7.6, 1X Denhardt's solution, 10% dextran sulfate, and 0.1% SDS, at a temperature of 42°C. Other conditions for high stringency hybridization, such as for PCR, Northern, Southern, or *in situ* hybridization, DNA sequencing, etc., are well-known by those skilled in the art of molecular biology. See, for example, F. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley &  
30 Sons, New York, NY, 1998.

By "familial mutation" or "inherited mutation" is meant a mutation in an individual that was inherited from a parent and that was present in somatic cells of the parent. By "sporadic mutation" or "spontaneous mutation" is meant a mutation in an individual that arose in the individual and was not present in a parent of the individual.

5 By "BMPR2 RNA function" is meant a function of the RNA other than the state of coding for an amino acid sequence. For example, BMPR2 RNA production, stability, processing (including splicing), transport, and the ability to be translated are BMPR2 RNA functions. By "altered BMPR2 RNA function" is meant an alteration of BMPR2 RNA function relative to the function of wild-type BMPR2 RNA.

10 As set forth herein, nucleotides are numbered according to the cDNA sequence for BMPR2 (SEQ ID NO:1), with the adenosine of the initiation codon assigned position 1. (Kawabata, M., Chytil, A. & Moses, H.L. Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-beta receptor. *J. Biol. Chem.* **270**, 5625-5630 (1995); Liu, F., Ventura, F.,  
15 Doody, J. & Massagué, J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. *Mol. Cell. Biol.* **15**, 3479-3486 (1995); Rosenzweig, B.L. *et al.* Cloning and characterization of a human type II receptor for bone morphogenetic proteins. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 7632-7636 (1995).

20 The nucleotide and amino acid sequence of BMPR2 are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively, starting at nucleotide 1 and amino acid 1, respectively. However, the wild-type cDNA sequence for BMPR2 which is set forth in Genbank Accession No. NM\_001204, assigns the adenosine of the initiation codon to position 409. Therefore, nucleotide position 1 used herein corresponds to nucleotide number  
25 409 of the BMPR2 cDNA sequence set forth in Genbank Accession No. NM\_001204. Thus, where a mutation is noted as being at, for example, nucleotide residue 1454, this corresponds to nucleotide residue 1862 of the sequence set forth in Genbank Accession No. NM\_001204 (that is, 1454 + 408).

30 As used herein, a specific notation will be used to denote certain types of mutations. All notations referencing a nucleotide or amino acid residue will be understood to correspond to the residue number of the wild-type BMPR2 nucleic acid

sequence set forth at SEQ ID NO:1, or of the wild-type BMPR-II polypeptide sequence set forth at SEQ ID NO:2. Thus, for example, the notation "T 367 C" will be used to indicate that the nucleotide T at position 367 of the sequence set forth at SEQ ID NO:1 has been replaced with a C. Similarly, the notation "355 del A" will be used to indicate  
5 that the nucleotide A at position 355 has been deleted. Furthermore, the notation 2408 ins TG" will be used to indicate that the nucleotides T and G, in that order, have been inserted following the nucleotide at position 2408.

In the method of the invention, the mutant BMPR-II polypeptide or mutated BMPR2 nucleic acid identified is associated with pulmonary hypertension.

10 In one embodiment, the subject having an increased susceptibility for developing pulmonary hypertension is identified by detecting a mutated BMPR2 nucleic acid in the subject. The mutated BMPR2 nucleic acid may comprise a missense mutation, that is, a mutation that changes a codon specific for one amino acid to a codon specific for another amino acid. As is noted below in the Examples and in Tables  
15 1, 2, and 4, examples of mutated BMPR2 nucleic acids having a missense mutation which are associated with pulmonary hypertension include C 218 G, T 354 G, T 367 C, T 367 A, C 428 T, C 993 T, G 1042 A, T1258 C, A 1454 G, A 1535 C, T 1557 A, and C 2695 T.

In another embodiment, the BMPR2 nucleic acid having a sequence associated  
20 with pulmonary hypertension comprises a nucleic acid sequence having an insertion mutation, where one or more nucleotides are inserted into the wild-type sequence. The mutated BMPR2 nucleic acid may also comprise a deletion mutation, where one or more nucleotides are deleted from the wild-type sequence. Such a deletion or insertion mutation may, for example, result in a frameshift mutation, altering the reading frame.  
25 Frameshift mutations typically result in truncated (that is, prematurely terminated) BMPR-II polypeptide. As is noted below in the Examples and in Tables 1, 2, and 4, examples of BMPR2 nucleic acids having an insertion mutation which are associated with pulmonary hypertension include 504 ins T, 2292 ins A, and 2408 ins TG. Examples of BMPR2 nucleic acids having a deletion mutation which are associated  
30 with pulmonary hypertension include 355 del A, 689 del A, 958 del T, 1076 del C, 1191/1192 del TG, and 2579 del T.

The mutated BMPR2 nucleic acid may also comprise a nonsense mutation, that is, a mutation that changes a codon specific for an amino acid to a chain termination codon. Nonsense mutations result in truncated (that is, prematurely terminated) BMPR-II polypeptide. As is set forth below in the Examples and in Table 1, examples of BMPR2 nucleic acids having a nonsense mutation which are associated with pulmonary hypertension include C 218 G, C 428 T, C 993 T, and C 2695 T.

The mutated BMPR2 nucleic acid may also comprise a truncation mutation, that is, a mutated BMPR2 nucleic acid which encodes a truncated BMPR-II polypeptide. This may occur where, for example, the BMPR2 nucleic acid has a nonsense mutation.

In another embodiment, the mutated BMPR2 nucleic acid can be truncated at a nucleotide position of the sequence set forth in SEQ ID NO:1 which is 3' to nucleotide position 2695 of the sequence set forth at SEQ ID NO:1. As is set forth below in the Examples, it has been determined that a mutation at nucleotide 2695, which truncates the BMPR-II polypeptide at amino acid residue 899, is correlated to pulmonary hypertension.

In another embodiment, the mutated BMPR2 nucleic acid comprises a mutation at a nucleotide position of the sequence set forth in SEQ ID NO:1 selected from the group consisting of nucleotide 218, 354, 355, 367, 428, 504, 689, 958, 993, 1042, 1076, 1129, 1191, 1258, 1454, 1535, 1557, 1749, 2292, 2408, 2579, and 2695. The mutation can result in a change in a codon such that the mutated codon now encodes a different amino acid. The mutation can result in a polypeptide having a non-conservative substitution at the relevant amino acid residue. One of ordinary skill will readily understand the concept of a "non-conservative substitution." Substitutions such as a charged amino acid for an uncharged amino acid, or an uncharged amino acid for a charged amino acid, or any amino acid in place of a Cys, or visa versa, or any amino acid in place of a Pro, or visa versa, are well known in the art to alter the structure and often the function of a protein. The mutation can also result in reduction or elimination of BMPR2 mRNA production, incorrect or altered processing of BMPR2 RNA, increased BMPR2 RNA instability, or other effects on expression of BMPR2 prior to translation. For example, the mutation 1129 CG (Table 1) alters a splice junction and

results in incorrect splicing of BMPR2 RNA. The mutation C 1749 T, which does not alter the encoded amino acid, likely affects RNA production, processing, or function.

In the embodiment wherein the mutation in the mutated BMPR2 nucleic acid results in a non-conservative substitution in the amino acid sequence encoded by the nucleic acid, the mutation in the mutated BMPR2 nucleic acid can be selected from the group consisting of C 218 G, T 354 G, T 367 C, T 367 A, C 428 T, C 993 T, G 1042 A, T1258 C, A 1454 G, A 1535 C, T 1557 A, C 2695 T. The non-conservative substitution may comprise at least one substitution at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of: a Trp residue at amino acid position 118, an Arg residue at amino acid position 123, a Ser residue at amino acid position 123, a Leu residue at amino acid position 143, an Ile residue at amino acid position 348, an Arg residue at amino acid position 420, an Ala residue at amino acid position 485, a Gln residue at amino acid position Gln, and a Lys residue at amino acid position 519.

In yet another embodiment, the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension encodes a mutant BMPR-II polypeptide.

For example, the mutant BMPR-II polypeptide having a sequence associated with pulmonary hypertension can comprise at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2. Preferably, the BMPR-II polypeptide comprises at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of 73, 118, 123, 143, 332, 348, 420, 485, 512, 519, and 899.

For example, the BMPR-II polypeptide acid having a sequence associated with pulmonary hypertension may comprise at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of: a Trp residue at amino acid position 118, an Arg residue at amino acid position 123, a Ser residue at amino acid position 123, a Leu residue at amino acid position 143, an Ile residue at amino acid position 348, an Arg residue at amino acid position 420, an Ala residue at amino acid position 485, a Gln residue at amino acid position Gln, and a Lys residue at amino acid position 519.

In another embodiment, the BMPR-II polypeptide having a sequence associated with pulmonary hypertension terminates prematurely. In a preferred embodiment, the BMPR-II polypeptide having a sequence associated with pulmonary hypertension terminates at an amino acid position of the sequence set forth in SEQ ID NO:2 which is  
5 at or N-terminal to amino acid position 899, including amino acid positions 73, 332, and 899.

In another embodiment, the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one amino acid residue of a BMPR-II having the amino acid sequence set forth in SEQ  
10 ID NO:2.

In one embodiment, the non-conservative amino acid substitution comprises a non-conservative amino acid substitution of any of the following: at least one Cys residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the non-conservative amino acid substitution comprises a non-conservative amino acid substitution of at least one Pro residue of a BMPR-II having  
15 the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the non-conservative amino acid substitution comprises a non-conservative amino acid substitution of at least one Lys residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the non-conservative amino acid substitution comprises a non-conservative amino acid substitution of at least one Arg  
20 residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the non-conservative amino acid substitution comprises a non-conservative amino acid substitution of at least one Asp residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the non-conservative amino acid substitution comprises a non-conservative amino acid  
25 substitution of at least one Glu residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

The mutated BMPR2 nucleic acid and mutant BMPR-II polypeptide that is detected can be from any cause. For example, mutated BMPR2 nucleic acid can be the  
30 result of a familial mutation or a sporadic mutation.

### Kits

The disclosed method is preferably carried out using a kit designed or adapted to detect one or more mutant BMPR-II polypeptides and/or one or more mutated BMPR2 nucleic acids. An example would be a kit for detecting a variety of mutated BMPR2 nucleic acids. Many such kits, and methods for using them are known.

### Nucleic Acid Delivery

BMPR-II biological activity can be stimulated (or correct activity provided) in a subject by administering to the subject a nucleic acid encoding BMPR-II, using any method known for nucleic acid delivery into the cells of a subject. The BMPR2 nucleic acid is taken up by the cells of the subject and directs expression of the encoded BMPR-II in those cells that have taken up the nucleic acid. The BMPR2 nucleic acids of the present invention can be in the form of naked DNA or RNA, or the nucleic acids can be within a vector for delivering the nucleic acids to the cells. The vector can be a commercially available preparation, such as an adenovirus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada). Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the nucleic acid or vector of this invention can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

As one example, vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome (see e.g., Pastan et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:4486, 1988; Miller et al., *Mol. Cell. Biol.* 6:2895, 1986). The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells a nucleic acid that encodes a BMPR-II polypeptide. The exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure

including the use of adenoviral vectors (Mitani et al., *Hum. Gene Ther.* 5:941-948, 1994), adeno-associated viral (AAV) vectors (Goodman et al., *Blood* 84:1492-1500, 1994), lentiviral vectors (Naidini et al., *Science* 272:263-267, 1996), pseudotyped retroviral vectors (Agrawal et al., *Exper. Hematol.* 24:738-747, 1996). Physical  
5 transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms (see, for example, Schwartzenberger et al., *Blood* 87:472-478, 1996). The present invention can be used in conjunction with any of these or other commonly used gene transfer methods.

In a particular example, to deliver a BMPR2 nucleic acid to the cells of a human  
10 subject in an adenovirus vector, the dosage can range from about  $10^7$  to  $10^9$  plaque forming unit (pfu) per injection but can be as high as  $10^{12}$  pfu per injection (Crystal, *Hum. Gene Ther.* 8:985-1001, 1997; Alvarez and Curiel, *Hum. Gene Ther.* 8:597-613, 1997). Ideally, a subject will receive a single injection. If additional injections are necessary, they can be repeated at six month intervals for an indefinite period and/or  
15 until the efficacy of the treatment has been established.

Parenteral administration of the nucleic acid or vector of the present invention, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently  
20 revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795. For additional discussion of suitable formulations and various routes of administration of therapeutic compounds, see, e.g., *Remington: The Science and Practice of Pharmacy* (19th ed.) ed. A.R. Gennaro, Mack Publishing Company,  
25 Easton, PA 1995.

#### Animal Models

Compounds identified as modulating BMPR2 or BMPR-II expression or proposed to affect PPH may be subsequently screened in any available animal model system, including, but not limited to, mice, rats, pigs, rabbits, and chickens (Smith, JD,  
30 *Lab. Anim. Sci.* 48:573-579, 1998; Narayanaswamy et al., *J. Vasc. Interv. Radiol.* 11:5-17, 2000; Poernama et al., *Atheroscler. Thromb.* 12:601-607, 1992; and Schreyer et al.,

- Atheroscler. Thromb.* 14:2053-2059, 1994). Test compounds are administered to these animals according to standard methods. Known animal models include monocrotalin injection, continuous air embolism, and fawn hooded rat. Some useful models are described by Johnson et al., Pulmonary veins and bronchial vessels undergo remodeling in sustained pulmonary hypertension induced by continuous air embolization into sheep, *Experimental Lung Research*. 23(5):459-73 (1997); Perkett et al., Expression of transforming growth factor-beta mRNAs and proteins in pulmonary vascular remodeling in the sheep air embolization model of pulmonary hypertension, *American Journal of Respiratory Cell & Molecular Biology*. 11(1):16-24 (1994); Perkett et al., Insulin-like growth factor I and pulmonary hypertension induced by continuous air embolization in sheep, *American Journal of Respiratory Cell & Molecular Biology*. 6(1):82-7 (1992); Perkett et al., Sequence of structural changes and elastin peptide release during vascular remodelling in sheep with chronic pulmonary hypertension induced by air embolization, *American Journal of Pathology*. 139(6):1319-32 (1991); Perkett et al., Continuous air embolization into sheep causes sustained pulmonary hypertension and increased pulmonary vasoreactivity, *American Journal of Pathology*. 132(3):444-54 (1988); Morio et al., Distal airspace enlargement in the fawn-hooded rat: influences of aging and alveolar wall destruction, *Respiration*. 68(1):78-86 (2001); Le Cras et al., Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude, *American Journal of Physiology - Lung Cellular & Molecular Physiology*. 279(2):L283-91 (2000); Le Cras et al., Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded rat, *American Journal of Physiology*. 277(4 Pt 1):L709-18 (1999); Gonzalez et al., The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence, *American Journal of Respiratory Cell & Molecular Biology*. 19(2):245-9 (1998); Gonzalez et al., Pulmonary hypertension, family and environment, *Journal of Human Hypertension*. 11(9):559-61 (1997); Provoost, Spontaneous glomerulosclerosis: insights from the fawn-hooded rat, *Kidney International - Supplement*. 45:S2-5 (1994); Sato et al., Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat, *American Review of Respiratory Disease*. 145(4 Pt 1):793-7 (1992); Ashmore et al., Paradoxical constriction to platelets by arteries from rats with

pulmonary hypertension, *American Journal of Physiology*. 260(6 Pt 2):H1929-34 (1991); Nagaya et al., Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats, *Circulation*. 102(16):2005-10 (2000); Shubat et al., Pulmonary vascular responses induced by the pyrrolizidine alkaloid, monocrotaline, in rats, *Toxicon*. 25(9):995-1002 (1987); Gust and Schuster, Vascular remodeling in experimentally induced subacute canine pulmonary hypertension, *Experimental Lung Research*. 27(1):1-12 (2001); Ito et al., Alterations of endothelium and smooth muscle function in monocrotaline-induced pulmonary hypertensive arteries, *American Journal of Physiology - Heart & Circulatory Physiology*. 279(4):H1786-95 (2000); Tanabe et al., Experimental study on monocrotaline induced pulmonary hypertensive rats. (1) Effect of long-term injection of immunosuppressant, *Tokai Journal of Experimental & Clinical Medicine*. 6(1):41-8 (1981); and Kameji et al., Increase of collagen synthesis in pulmonary arteries of monocrotaline-treated rats, *Experientia*. 36(4):441-2 (1980).

Animal models that mimic PPH can be developed using conventional molecular biology methods. For example, a transgenic animal (for example, a mouse) that overexpresses BMPR2 can be generated by inserting a BMPR2-encoding nucleic acid under the transcriptional regulation of the appropriate tissue-specific promoter into the genome of the animal.

## **Test Compounds**

In general, novel drugs that modulate BMPR-II biological activity may be identified from large libraries of natural products or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (for example, semi-synthesis or total synthesis) of any number of

chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available, e.g., from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of  
5 bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are generated, if desired, according to methods known in the art, for example, by standard extraction and  
10 fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (for example, taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the  
15 elimination of replicates or repeats of materials already known for their BMPR-II-modulatory activities should be employed whenever possible.

When a crude extract is found to modulate BMPR-II activity, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and  
20 purification process is the careful characterization and identification of a chemical entity within the crude extract having an activity that mimics, stimulates, or antagonizes BMPR-II, depending upon the effect desired. The same assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of  
25 such heterogenous extracts are known in the art. If desired, compounds shown to be useful agents for treatment are chemically modified according to methods known in the art. Compounds identified as being of therapeutic value can be subsequently analyzed using any animal models for PPH.

#### **Administration of compounds that modulate BMPR-II biological activity**

30 The compositions and methods described herein can be used therapeutically in combination with a pharmaceutically acceptable carrier. By "pharmaceutically

acceptable carrier" is meant a material that is not biologically or otherwise undesirable, that is, the material may be administered to an individual along with a polypeptide, nucleic acid, or other compound of the invention without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the pharmaceutical composition in which it is contained. Pharmaceutical carriers are well-known in the art. These most typically are standard carriers for administration of vaccines or pharmaceuticals to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH.

Molecules intended for pharmaceutical delivery may be formulated in a pharmaceutical composition. Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like. Methods for making such formulations are well known in the art, and are described, for example, in: *Remington: The Science and Practice of Pharmacy* (19<sup>th</sup> ed.), ed. A.R. Gennaro, E.W. Martin Mack Publishing Co., Easton, PA, 1995.

The pharmaceutical compositions may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection. The compounds and compositions of the present invention can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on

Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable. Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

The compounds of the invention are administered in an effective amount, using standard approaches. Effective dosages and schedules for administering the compounds may be determined empirically, and making such determinations is routine to one of ordinary skill in the art. The skilled artisan will understand that the dosage will vary, depending upon, for example, the species of the subject the route of administration, the particular compound to be used, other drugs being administered, and the age, condition, sex and extent of the disease in the subject. The dosage can be adjusted by the individual physician in the event of any counterindications. A dose of a compound of the invention generally will range between about 1  $\mu\text{g/kg}$  of body weight and 1 g/kg of body weight. Examples of such dosage ranges are, e.g., about 1  $\mu\text{g}$ -100  $\mu\text{g/kg}$ , 100  $\mu\text{g/kg}$ -10 mg/kg, or 10 mg-1 g/kg, once a week, bi-weekly, daily, or two to four times daily. Compounds of the invention include BMPR-II polypeptides, BMPR2 nucleic acids, and molecules that regulate expression and/or biological activity of endogenous wild-type, polymorphic, and/or mutant BMPR-II polypeptides and/or nucleic acids (for example, DNA or RNA molecules) encoding such BMPR-II polypeptides.

The following Examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds,

compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.

### Examples

#### 5 Example 1

This example describes identification of BMPR2 mutations associated with susceptibility to PPH. To enable positional cloning of the FPPH gene (*PPHI*) a published YAC map was verified and extended at 2q33 to anchor a BAC/PAC contig including genomic sequences available at GenBank (Hadano, S. *et al.* A yeast artificial  
10 chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33-q34. *Genomics* 55, 106-112 (1999)). This contig covers the entire 5.8 Mb *PPHI* region defined by recently detected recombination events limited by the polymorphic STS markers *D2S115* and *D2S1384* (ref.12), and includes the nucleotide sequence encoding bone morphogenetic protein  
15 receptor type II (BMPR-II).

PCR primers were designed for amplification of patient genomic DNA after determination of the intron/exon boundaries of BMPR2. Sequence variants were identified from the panel of kindreds studied. Heterogeneous mutations, including frameshift, nonsense and missense mutations, were identified. These mutations were  
20 distributed across the gene.

Either restriction enzyme or sequence analysis of DNA from affected and unaffected first-degree relatives was used to show co-segregation of the mutations with the disease phenotype (including obligate gene carriers) in all but one of the pedigrees. 150 normal chromosomes derived from the same population as the affected families  
25 were screened together with a panel of 64 chromosomes from normal, but ethnically diverse, controls subjects. None of the mutations were detected in either panel.

### Materials and Methods

#### Patients

We ascertained families in which at least two members had the typical  
30 manifestations of PPH after exclusion of known associated disorders, as previously described (5). We collected venous blood samples and extracted genomic DNA

following informed consent. Obligate gene carriers are defined as those individuals who inherit and transmit the disease gene to an affected offspring but who themselves show no clinical manifestations of the disease.

#### **Determination of the genomic structure of BMPR2**

- 5 Available genomic sequence of BAC RP11-354N12  
(<http://www.ncbi.nlm.nih.gov/> Genbank) was compared to the published cDNA  
sequence (Genbank Z48923) and the intron/exon boundaries for the 3' portion of the  
gene (exons 8-13) determined (14). To determine the intron/exon boundaries for exons  
1-7, additional BAC clones were isolated by PCR screening of a human genomic BAC  
10 library (CITB B&C, Research Genetics) using both an exon 1 and exon 3 STS designed  
from the BMPR2 cDNA. Direct sequence analysis of the BAC clones with primer  
predicted to be near intron/exon junctions, based on the mouse *Bmpr2* genomic  
structure, generated flanking intronic sequence for the remaining introns (18).  
Comparison between the human and published mouse genomic organization shows  
15 strong conservation of the intron/exon boundaries (18).

#### **Mutational analysis**

- We screened the entire coding and intron/exon boundaries by direct sequencing  
of both forward and reverse strands on either an ABI 377 sequencer or an ABI 3700  
DNA analyzer, using the Applied Biosystems DyeDeoxy or BigDye terminator kit and  
20 analysed the data using Sequence Analysis v3.2 or v3.6NT software (Perkin Elmer).

The PCR primers for each exon were:

Exon1: 5'-AGCTAGGTCCTCTCATCAGC-3' (SEQ ID NO:3)

5'-CAGCCGCAGTGCTGACCAGC-3' (SEQ ID NO:4);

Exon2: 5'-GTCATTCGGATAAGACAAAG-3' (SEQ ID NO:5)

- 25 5'-TTTAACATACTCCCATGTCC-3' (SEQ ID NO:6);

Exon3: 5'-TAGCTTACACGTACTCTCAC-3' (SEQ ID NO:7)

5'-CCTGGCTTCAACCTTGAATG-3' (SEQ ID NO:8);

Exon4: 5'-GGGTACAGCCTTTCTAAAGG-3' (SEQ ID NO:9)

5'-GATACTATTGAGGCTGGGTG-3' (SEQ ID NO:10);

- 30 Exon5: 5'-GCTGCTAATCTTTCTGCAGC-3' (SEQ ID NO:11)

5'-GAATGAAGTCACTGTTCCAG-3' (SEQ ID NO:12);

- Exon6: 5'-CAGAGAGCTGTAGCATTCTG-3' (SEQ ID NO:13)  
 5'-AAGTGATCCACCTGCCTTAG-3' (SEQ ID NO:14);  
 Exon7: 5'-ACTCTTCATGTAAAGTGAG-3' (SEQ ID NO:15)  
 5'-CTTTGAAGATATAATTAATAATTTCC-3' (SEQ ID NO:16);  
 5 Exon8: 5'-CACCTGGCCAGTAGATGTTT-3' (SEQ ID NO:17)  
 5'TGTTCAATAGTCCCTTTTATTCATTG-3' (SEQ ID NO:18);  
 Exon9: 5'-CTAATTTGCATCCTGCTGCT-3' (SEQ ID NO:19)  
 5'-TGTTCTTCAGAATATGCTACG TTCTC-3' (SEQ ID NO:20);  
 Exon10: 5'-TTGTGGCATTAGGCAACTCC-3' (SEQ ID NO:21)  
 10 5'-GCCTGAAGGGGATGAA AAA-3' (SEQ ID NO:22);  
 Exon11: 5'-CCACACCCCTTAGGGTCTTA-3' (SEQ ID NO:23)  
 5'-CACATGGTTTGACATGTAC TTTG-3' (SEQ ID NO:24);  
 Exon12A: 5'-CATCAGAGCTTTTCCTTGAGGTT-3' (SEQ ID NO:25)  
 5'-CAGAGGTGTTAAATTT GGAG-3' (SEQ ID NO:26);  
 15 Exon12B: 5'-TCTACCTGCCACACCATTCA-3' (SEQ ID NO:27)  
 5'-TGGAACCAACAAGCTAGACC-3' (SEQ ID NO:28);  
 Exon12C: 5'-CCCCAAAAGACACACAGGAG-3' (SEQ ID NO:29)  
 5'-TGAATGGTGTGGCAGGTAGA-3' (SEQ ID NO:30);  
 Exon13: 5'-GCTGACAGGAGGATAAAGCA-3' (SEQ ID NO:31)  
 20 5'-CACCTCCTGAGACATTGGT-3' (SEQ ID NO:32).

#### **Restriction endonuclease digestion**

We confirmed segregation of the mutations within families and excluded the presence of the mutations in controls, including a panel from the DNA Polymorphism Discovery Resource, Coriell Cell Repositories, by PCR amplification of the relevant  
 25 exon. This was followed by either mutation specific restriction fragment length polymorphism (RFLP) analysis or direct sequencing as previously described (23). Exon 12 (2579-2580delT) was PCR amplified using the following primers as a nested PCR reaction: 5' ACCCAATATGCCAATGGGAC-3' (SEQ ID NO:33), 5'-  
 TTCGCCACCTTCTAGTGGCT-3' (SEQ ID NO:34) followed by 5'-  
 30 CATGTGGTAAACTGAAAAGCTCA-3' (SEQ ID NO:35), 5'-  
 TTGAGACCACTTTGATACACACA-3' (SEQ ID NO:36). We digested an aliquot (10

μl) overnight at 37°C with the appropriate enzyme (10U; Gibco) and separated the fragments on a 4% agarose gel.

In keeping with the recognized reduced penetrance of FPPH, some individuals over 40 years of age exhibited the restriction fragments of a mutant but were not affected (individuals 6 and 10 in NL01). Nucleic acid mutations included A 1454 G (exon 11, *Ava*II, pedigree NL01), T 354 G (exon 3, *Bsp*1286I, pedigree US14), 2579-2580 delT (exon 12, *Ase*I, pedigree US55), C 2695 T (exon 12, *Hae*III, pedigree US33), 355 del A (exon 3, *Bsp*1286I, pedigree UK13), G 1042 A (exon 8, pedigree UK06), and C 218 G (exon 2, pedigreeUS35). Polypeptide mutations included D 485 G (pedigree NL01), C 118 W (pedigree US14), PTC + 10aa (pedigree US55), R 899 X (pedigree US33), PTC + 8aa (pedigree UK13), C 347 Y (pedigree UK06), and S 73 X (pedigree US35). The downstream amino acid position of the premature termination codon (PTC) is indicated by the designation "+ Xaa" where X is number of amino acids downstream of the codon that is mutated. Sequence analysis of both forward and reverse strands was performed for those PPH families in which the observed mutation did not create or destroy a restriction site: G 1042 A (exon 8, pedigree UK06), and C 218 G (exon 2, pedigreeUS35).

### Discussion

Members of the TGF-β superfamily transduce signals by binding to heteromeric complexes of type I and II receptors, activating serine/threonine kinases, leading to transcriptional regulation by phosphorylated Smads (Massagué, J. & Chen, Y-G. Controlling TGF-β signalling. *Genes Dev.* **14**, 627-644 (2000)). In FPPH, mutations in the gene encoding BMPR-II lead to alterations in domains which have been identified in TGF-β type II receptors as being involved in ligand binding, kinase activity and heteromeric dimer formation (Wrana, J.L. *et al.* Two distinct transmembrane serine/threonine kinases from *Drosophila melanogaster* form an activin receptor complex. *Mol. Cell. Biol.* **14**, 944-950 (1994); Carcamo, J., Zentella, A. & Massagué, J. Disruption of transforming growth factor beta signalling by a mutation that prevents transphosphorylation within the receptor complex. *Mol. Cell. Biol.* **15**, 1573-1581 (1995); Gilboa, L. *et al.* Bone morphogenetic protein receptor complexes on the surface

of live cells: A new oligomerization mode for serine/ threonine kinase receptors. *Mol. Biol. Cell.* **11**, 1023-1035 (2000)).

### References

1. Rubin, L. ACCP consensus statement: primary pulmonary hypertension. *Chest* **104**, 236-250 (1993).
2. Gaine, S.P. & Rubin, L.J. Primary pulmonary hypertension. *Lancet* **352**, 719-725 (1998).
3. Rich, S. *et al.* Primary pulmonary hypertension: a national prospective study. *Ann. Intern. Med.* **107**, 216-223 (1987).
4. Loyd, J.E., Primm, R.K. & Newman, J.H. Familial primary pulmonary hypertension: clinical patterns. *Am. Rev. Respir. Dis.* **129**, 194-197 (1984).
5. Nichols, W.C. *et al.* Localisation of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. *Nature Genet.* **15**, 277-280 (1997).
6. Morse, J.H. *et al.* Mapping of familial pulmonary hypertension locus (*PPH1*) to chromosome 2q31-32. *Circulation* **95**, 2603-2606 (1997).
7. Massagué, J. & Chen, Y-G. Controlling TGF- $\beta$  signalling. *Genes Dev.* **14**, 627-644 (2000).
8. Wrana, J.L. *et al.* Two distinct transmembrane serine/threonine kinases from *Drosophila melanogaster* form an activin receptor complex. *Mol. Cell. Biol.* **14**, 944-950 (1994).
9. Carcamo, J., Zentella, A. & Massagué, J. Disruption of transforming growth factor beta signalling by a mutation that prevents transphosphorylation within the receptor complex. *Mol. Cell. Biol.* **15**, 1573-1581 (1995).
10. Gilboa, L. *et al.* Bone morphogenetic protein receptor complexes on the surface of live cells: A new oligomerization mode for serine/ threonine kinase receptors. *Mol. Biol. Cell.* **11**, 1023-1035 (2000).
11. Hadano, S. *et al.* A yeast artificial chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33-q34. *Genomics* **55**, 106-112 (1999).

13. Kawabata, M., Chytil, A. & Moses, H.L. Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-beta receptor. *J. Biol. Chem.* **270**, 5625-5630 (1995).
14. Liu, F., Ventura, F., Doody, J. & Massagué, J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. *Mol. Cell. Biol.* **15**, 3479-3486 (1995).
15. Rosenzweig, B.L. *et al.* Cloning and characterization of a human type II receptor for bone morphogenetic proteins. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 7632-7636 (1995).
16. Botney, M.D., Bahadori, L. & Gold, L.I. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. *Am. J. Pathol.* **144**, 286-295 (1994).
17. Marchuk, D.A. Genetic abnormalities in hereditary hemorrhagic telangiectasia. *Curr. Opin. Hematol.* **5**, 332-338 (1998).
18. Beppu, H., Minowa, O., Miyazono, K. & Kawabata, M. cDNA cloning and genomic organization of the mouse BMP type II receptor. *Biochem. Biophys. Res. Commun.* **235**, 499-504 (1997).
19. Wilkie, A.O. The molecular basis of genetic dominance. *J. Med. Genet.* **31**, 89-98 (1994).
20. 21. Lu, S.L. *et al.* HNPCC associated with germline mutation in the TGF-beta type II receptor gene. *Nature Genet.* **19**, 17-18 (1998).
22. Lee, S.D. *et al.* Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. *J. Clin. Invest.* **101**, 927-934 (1998).
- Shackleton, S. *et al.* LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nature Genet.* **24**, 153-156 (2000).

## Example 2

### Materials and Methods

#### Patients

- 30 Patients (age range 14-55 years) were recruited through physicians at specialist pulmonary vascular clinics in the UK (n=35), France (n=13) and the USA (n=2). PPH

was defined by standard clinical methods, including cardiac catheterization revealing pulmonary hypertension (mean pulmonary artery pressure > 25 mm Hg) and a normal pulmonary artery wedge pressure, without other abnormalities such as lung disease, heart disease, pulmonary embolism or systemic disease such as connective tissue diseases. All studies were performed with consent and approval by the Leicestershire Health Authority Ethics Committee (England).

#### Typical Presentation

At age 36, patient 10 a previously fit and well nulliparous white female, developed shortness of breath and reduced exercise tolerance. She had no previous history of tobacco consumption, nor use of appetite suppressants. A five generation detailed pedigree revealed no preceding family history of PPH. The following year, she was investigated for worsening breathlessness. On clinical examination, external appearance was normal, cardiac auscultation revealed a loud second pulmonary heart sound. A radiograph of the chest showed enlarged pulmonary arteries with 'pruning' of peripheral vessels, electrocardiogram had evidence of right ventricular strain and an echocardiogram revealed an enlarged right ventricle and moderate tricuspid regurgitation. An autoantibody screen and ventilation/ perfusion scan were normal. At right heart catheterisation, pulmonary artery pressure was 97/41 mmHg with a pulmonary wedge pressure of 8 mmHg, and a diagnosis of primary pulmonary hypertension was made. The patient was anti-coagulated on warfarin and commenced on a calcium channel blocking agent, diltiazam. Her condition deteriorated over the following year with increasing episodes of retro-sternal chest pain, haemoptysis, syncope and the development of peripheral oedema. Domiciliary oxygen was provided and she was assessed for heart-lung transplantation, which she received at age 41. Histology of the explanted lungs showed marked intimal expansion and atheromatous plaques in the main branches of pulmonary arteries. Distal arteries showed hypertrophied muscularised media, intimal expansion and obliteration, with formation of plexiform lesions. The alveoli and bronchi appeared normal. A year following transplant she returned to work and remains under follow-up on a regime of immuno-suppression.

### DNA Sequence Analysis of BMPR2 gene

We obtained 10 to 20 ml of peripheral blood from each family member studied. DNA was isolated from whole blood as described elsewhere. Parental relationships were confirmed through the segregation analysis of 10 independent highly polymorphic markers. Protein coding sequences from exons 1 to 13 were amplified from genomic DNA using primers derived from intron sequence as described in Example 1. Genomic fragments amplified by the polymerase chain reaction (PCR) were sequenced with a dye-terminator cycle-sequence system (ABI 3700, Perkin-Elmer Applied Biosystems, Foster City, CA).

### Confirmation of Genotypes and Detection of Spontaneous (*de novo*) Mutations

Variants of the BMPR2 gene were identified by sequence analysis and, when possible, were independently confirmed by restriction endonuclease digestion. Relevant exons were PCR amplified using primers as described, digested with restriction enzymes (*Hae* III, *Taq* I, *Mse* I, *Fnu*4H I, New England Biolabs) according to the manufacturer's instructions, and size-separated on a 4% composite agarose gel (FMC BioProducts, Gibco BRL). The presence or absence of the sequence variants from available family members and at least 150 normal control chromosomes was determined by analysis of the restriction digest or direct sequencing results.

### Results

#### Analysis of the BMPR2 Gene

Sequencing of genomic DNA of the panel of sporadic PPH subjects demonstrated a variety of novel heterozygous mutations of the BMPR2 gene (Table 4). In patients 1 and 2, the nucleotide sequence revealed substitutions of guanine for adenine in exons 2 and 3 respectively. These change the sequences of codon 60 from TGC to TAC (patient 1) and codon 117 from TGT to TAT (patient 2); both changing a highly conserved encoded amino acid from cysteine to tyrosine (Table 4). As these mutations do not result in either gain or loss of a restriction site, genomic sequencing of parental samples demonstrated the presence of the mutation in the fathers of both sporadic patients.

In patient 8, genomic sequencing identified a substitution of thymine for cytosine in exon 11, changing the sequence of codon 483 from TGT to CGT and the encoded amino acid from cysteine to arginine (Table 2). No additional family members were available for study. In patients 6 and 10, deletion of an adenine in exon 9 and a  
5 guanine in exon 12 both lead to a change in the coding reading frame, and predict premature truncation of the 1038 amino-acid protein at codon positions 423 and 803 respectively. Analysis of samples from unaffected parents, either by direct sequencing of genomic DNA (patient 6) or restriction enzyme analysis with *Fnu4HI* (patient 10), demonstrated the absence of the mutation, confirming these patients had spontaneous  
10 mutations of the *BMPR2* gene (Table 4).

The possibility of incorrect paternity was excluded by the analysis of informative markers. The mutation observed in patient 10, was also detected in two further sporadic patients, 11 and 12 ascertained independently. No parental samples were available and the possibility of the patients having inherited the mutation from a  
15 common ancestor was excluded through the examination of genotypes from microsatellite markers from within and surrounding the *BMPR2* gene on chromosome 2.

In three additional patients, insertions of residues in the genomic sequence occurred. In patient 4, an additional thymine was detected in exon 6 at position 787  
20 (Table 4). In patient 7 both a guanine and adenine were inserted at nucleotide position 1247-8 of exon 9, while in patient 9 an adenine is inserted in exon 12 at position 1969 and confirmed through restriction digest analysis with *Mse* 1 (Table 4). Each of the mutations predicts premature truncation of the *BMPR-II* protein through shifts of the reading frame (Table 4). Parental material was not available for analysis for these  
25 subjects.

In patients 3 and 5, the substitution of cytosine for thymine occurred in exons 6 and 8 respectively (Table 4). In both patients the mutations result in the change of the encoded amino-acid arginine CGA to the stop signal TGA. These sequence changes were confirmed by restriction digest analysis of genomic DNA with *HaeIII* and *TaqI*  
30 respectively; however samples from other family members were not available.

None of these sequence changes were detected in the analysis of a large panel of chromosomes from unrelated normal individuals, indicating that these mutations are not polymorphisms. Mutations of the entire coding sequence of the BMPR2 gene were also excluded in the remaining 38 patients diagnosed with sporadic PPH.

5           **Pulmonary artery myocytes from patients with familial and sporadic PPH exhibit abnormal responses to TGF- $\beta$  family ligands**

PPH myocytes exhibited specifically heightened  $^3\text{H}$ -thymidine incorporation to BMP2, a known BMPR-II ligand, and TGF- $\beta$ . In contrast, no increased DNA synthesis was observed in response to these peptides in cells from control subjects or patients  
10 with secondary pulmonary hypertension. Indeed, TGF- $\beta$  suppressed basal  $^3\text{H}$ -thymidine incorporation in pulmonary artery myocytes from controls. PDGF- $\beta$  stimulated  $^3\text{H}$ -thymidine incorporation by an equal amount in all cells, with no significant difference between patient groups. Growth arrested pulmonary artery myocytes from patients with PPH were used. Incubations were for 48 hours with  
15 [methyl]- $^3\text{H}$ -thymidine added for final 24 hours. All subjects were age-matched and patients had a comparable degree of pulmonary hypertension: PPH (mean pulmonary artery pressure 604 mmHg); SPH (655 mmHg). \* $p < 0.05$ , \*\* $p < 0.01$  compared with corresponding 0.1% FBS.

**References**

- 20           1. Rubin LJ. Primary Pulmonary Hypertension. The New England Journal of Medicine 1997; 336:111-117.
2. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719-725.
3. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre  
25 KM, et al. Primary pulmonary hypertension. A national prospective study. Ann.Intern.Med. 1987; 107:216-223.
4. Loyd JB, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am.Rev.Respir.Dis. 1984; 129:194-197.
5. Machado RD, Pauciulo MW, Fretwell N, Veal C, Thomson JR, Güell  
30 CV, et al. A physical and transcript map based upon refinement of the critical interval

for PPH1, a gene for familial primary pulmonary hypertension. Genomics 2000; In press.

6. Nichols WC, Koller DL, Slovis B, Foroud TM, Terry VH, Arnold ND, et al. Localization of the gene for familial primary pulmonary hypertension to  
5 chromosome 2q31-32. Nat.Genet. 1997; 15:277-280.
7. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95:2603-2606.
8. Deng Z, Haghighi F, Helleby L, Vanterpool K, Horn EM, Barst RJ, et al.  
10 Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3 cM region on chromosome 2q33. American Journal of Respiratory & Critical Care Medicine 2000; 161:1055-1059.
9. The International PPH Consortium, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips III JA, et al. Heterozygous germline mutations in a TGF- $\beta$   
15 receptor, BMPR2, are the cause of familial primary pulmonary hypertension. Nat.Genet. 2000; In press.
10. Massague J, Chen YG. Controlling TGF- $\beta$  signaling. Genes & Development 2000; 14:627-644.
11. Loyd JE, Atkinson JB, Pietra GG, Virmani R, Newman JH.  
20 Heterogeneity of Pathologic Lesions in Familial Primary Pulmonary Hypertension. Am.Rev.Respir.Dis. 1988; 138:952-957.
12. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study o f pulmonary blood vessels from 58 patients in the National Heart, Lung, and  
25 Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80:1198-1206.
13. Elliott G, Alexander G, Leppert M, Yeates S, Kerber R. Coancestry in apparently sporadic primary pulmonary hypertension. Chest 1995; 108:973-977.
14. Morrell NW, Upton PD, Kotecha S, Huntley A, Yacoub MH, Polak JM,  
30 et al. Angiotensin II activates MAPK and stimulates growth of human pulmonary

artery smooth muscle via AT1 receptors. *American Journal of Physiology* 1999; 277:L440-L448

15. Rich S. Primary pulmonary hypertension. Executive summary from the world symposium. *Primary Pulmonary Hypertension*. World Health Organisation Publications 1998;
16. Marchuk DA. Genetic abnormalities in hereditary hemorrhagic telangiectasia. *Current Opinion in Hematology* 1998; 5:332-338.
17. Blobel GC, Schiemann WP, Lodish HF. Role of transforming growth factor  $\beta$  in human disease. *N Engl J Med* 2000; 342:1350-1358.
18. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. *Mayo Clinic Proceedings* 1998; 73:37-45.
19. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group [see comments]. *N.Engl.J.Med.* 1996; 335:609-616.
20. Gomez-Sanchez MA, Saenz dC, Gomez-Pajuelo C, Martinez-Tello FJ, Mestre dJM, James TN. Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome. *Journal of the American College of Cardiology* 1991; 18:1539-1545.
21. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tudor RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. *Journal of Clinical Investigation* 1998; 101:927-934.
22. Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, et al. HNPCC associated with germline mutation in the TGF- $\beta$  type II receptor gene. *Nat.Genet.* 1998; 19:17-18.

TABLE 1

Family/Pt	Location	Mutation	Nucleotide change	Consequence	Segregation
+UK13	Exon 3	Deletion	355delA GCTGTTGTA	frameshift	<i>Bsp</i> 1286I
UK09	Exon 3	C123R	367 TC	missense	<i>Mse</i> I
UK21	Exon 4	Insertion	504insT GTTGCCCTTT	frameshift	
FRA	Exon 6	Deletion	689/90delAA TGCTGTAAA	frameshift	DS
+UK06	Exon 8	C347T	G1042A	missense	DS
GER01	Exon 9	C420R	T1258C	missense	<i>Afa</i> I/ <i>Bsp</i> 1407I/ <i>Bsr</i> GI/ <i>Ssp</i> BI/ <i>Mae</i> I
+NL01	Exon 11	D485G	A1454G	missense	<i>Ava</i> II
GRE01	Exon 11	L512T	A1535 C	missense	
SWE01	Exon 12	R584X	C1749T	nonsense	
UK22	Exon 12	Insertion	2292insA ACCAAAAA	frameshift	DS
UK11	Exon 12	Deletion	2579-2580delT ATTAATT	frameshift (PTC + 10 aa)	<i>Ase</i> I
UK04	Exon 7	Deletion	958+3 delT AGGAGGTA	inactivates exon 7 donor splice site	
+US35	Exon 2	S73X	C218G	nonsense	DS
+US14	Exon 3	C118W	T354G	missense	<i>Bsp</i> 1286I
+US33	Exon 12	R899X	C2695T	nonsense	<i>Hae</i> III
+US55	Exon 12	Deletion	2579-2580delT ATTAATT	frameshift (PTC + 10 aa)	<i>Ase</i> I
US94	Exon8	Deletion	1076delC GGCTGAC	frameshift (PTC+ 15 aa)	
US89	Exon 9	Deletion	1191/1192delTG GGACTGTG	frameshift (PTC + 48 aa)	
US80	Exon 9	Splice Defect	1129-3CG	inactivates exon 9 acceptor splice site	
US37	Exon 4	R147X	C428T	nonsense	
US49	Exon 11	N519K	T1557A	missense	DS
US79	Exon 12	Insertion	2408insTG TGGTGTG	frameshift (PTC + 3 aa)	
NOR01	Exon 3	C123S	T367A	missense	<i>Mse</i> I
US50	Exon 8	R332X	C993T	nonsense	

TABLE 2

Patient	Location	Mutation	Nucleotide change	Consequence	Segregation	Mat	Pat	Centre
5226	Exon 2	C60Y	G179A	missense	DS	WT	C196Y	Manchester
3576	Exon 6	Insertion	TTTATAGTTT	frameshift	DS	Declined	Declined	Newcastle
5949	Exon 6	R211X	C631T	nonsense	<i>Hae</i> III	Alive, sample being arranged	Alive, sample being arranged	France
5591	Exon 8	R332X	C994T	nonsense	<i>Tag</i> I	Alive, to arrange sample	Alive, to arrange sample	CXH
5508	Exon 9	Insertion	GGGAGAGA 1247/48insGA	frameshift	DS	Alive, to arrange sample	?	Glasgow
5927	Exon 11	C483R	T1447C	missense	DS	Blood sample taken	?	France
5545	Exon 12	Insertion	TCTGCTTAA 1969insA	frameshift	<i>Mse</i> I	WT	RIP	Newcastle
5163	Exon 12	Deletion	CAATCAATG 2386delG	frameshift	<i>Fnu</i> 4HI	WT	WT	Harefield
5937	Exon 12	Deletion	CAATCAATG 2386delG	frameshift	<i>Fnu</i> 4HI	To request	To request	France
5943	Exon 12	Deletion	CAATCAATG 2386delG	frameshift	<i>Fnu</i> 4HI	To request	To request	France
Ut. 01	Exon 9	Deletion	GGGAGATA 1248delA	frameshift	DS	WT	WT	Utah
Ut. 11	Exon 3	C117Y	350G--A	missense	DS	WT	C117Y	Utah

Characteristics	1	2	3	4	5	6	7	8	9	10	11	12
Sex	F	M	F	F	F	M	M	F	F	F	F	M
Age (years)	23	31		27	35	29	42	34	34	43		
Age of onset (years)	17	25		22	29	22		30	30	36		
Family History	-	-	-	-	-	-	-	-	-	-	-	-
Therapy (vasodilators)	+	+	+	+	+	-	+	+	+	-	+	+
HLT	-	-	-	-	-	+	-	-	-	+	-	-
Mutation	C60Y	C117Y	R211X	787 <sup>InsT</sup>	R332X	1248-delA	1247/48-insGA	C483R	1969-insA	2386-delG	2386-delG	2386-delG
BMPR2												

Table 3. Clinical features of PPH.

Patient No.	Patient Identifier	Exon	Mutation Type	Nucleotide Change	Codon Position	Amino Acid Change	Inheritance	Restriction Enzyme
1	5226	2	Missense	G(179) A	60	Cys to Tyr	Paternal	-
2	Ut.11	3	Missense	G(350) A	117	Cys to Tyr	Paternal	
3	3576	6	Frameshift	787insT	263	PTC+3		
4	5949	6	Nonsense	C(631) T	211	Arg to Stop	-	<i>HaeIII</i>
5	5591	8	Nonsense	C(994) T	332	Arg to Stop	-	<i>TaqI</i>
6	Ut.01	9	Frameshift	1248delA	416	PTC+7	<i>de novo</i>	-
7	5508	9	Frameshift	1247/8ins GA	416	PTC+4	-	-
8	5927	11	Missense	T(1447) C	483	Cys to Arg	-	-
9	5545	12	Frameshift	1969insA	657	PTC+18	-	<i>MseI</i>
10	5163	12	Frameshift	2386delG	796	PTC+7	<i>de novo</i>	<i>Fnu4HI</i>
11	5937	12	Frameshift	2386delG	796	PTC+7	-	<i>Fnu4HI</i>
12	5943	12	Frameshift	2386delG	796	PTC+7	-	<i>Fnu4HI</i>
13	5597	1-6	Deletion					

Table 4. Mutations identified.

It must be noted that as used herein and in the appended claims, the singular forms "a ", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to "the antibody" is a reference to one or more antibodies and  
5 equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention,  
10 the preferred methods, devices, and materials are as described.

## CLAIMS

We claim:

1. A method of identifying a subject having an increased susceptibility for developing pulmonary hypertension, comprising detecting a mutant Bone Morphogenic Protein Receptor II (BMPR-II) polypeptide or a mutated Bone Morphogenic Protein Receptor 2 (BMPR2) nucleic acid in the subject, thereby identifying a subject having an increased susceptibility for developing pulmonary hypertension.
2. The method of claim 1, wherein the subject having an increased susceptibility for developing pulmonary hypertension is identified by detecting a mutated BMPR2 nucleic acid in the subject.
3. The method of claim 2, wherein the mutated BMPR2 nucleic acid encodes a mutant BMPR-II polypeptide.
4. The method of claim 2 wherein the mutated BMPR2 nucleic acid comprises a missense mutation.
5. The method of claim 2, wherein the mutated BMPR2 nucleic acid comprises a nonsense mutation.
6. The method of claim 2, wherein the mutated BMPR2 nucleic acid comprises a deletion mutation.
7. The method of claim 2, wherein the mutated BMPR2 nucleic acid comprises an insertion mutation.
8. The method of claim 2, wherein the mutated BMPR2 nucleic acid comprises a truncation mutation.
9. The method of claim 8, wherein the mutated BMPR2 nucleic acid is truncated at a nucleotide position of the sequence set forth in SEQ ID NO:1 which is 3' to nucleotide position 2695.
10. The method of claim 2, wherein the mutated BMPR2 nucleic acid comprises a nucleotide sequence that differs from the sequence set forth in SEQ ID NO:1.
11. The method of claim 1, wherein the mutated BMPR2 nucleic acid or mutant BMPR-II polypeptide has a sequence associated with pulmonary hypertension.

12. The method of claim 11, wherein the mutated BMPR2 nucleic acid comprises a mutation at a nucleotide position of the sequence set forth in SEQ ID NO:1 selected from the group consisting of 218, 354, 355, 367, 428, 504, 689, 958, 993, 1042, 1076, 1129, 1191, 1258, 1454, 1535, 1557, 1749, 2292, 2408, 2579, and 2695.

13. The method of claim 12, wherein the mutation in the mutated BMPR2 nucleic acid results in a non-conservative substitution in the amino acid sequence encoded by the nucleic acid.

14. The method of claim 13, wherein the mutation in the mutated BMPR2 nucleic acid results in a non-conservative substitution at a Cys residue encoded by the nucleotide sequence set forth in SEQ ID NO:1.

15. The method of claim 13, wherein the mutation is selected from the group consisting of C 218 G, T 354 G, T 367 C, T 367 A, C 428 T, C 993 T, G 1042 A, T 1258 C, A 1454 G, A 1535 C, T 1557 A, C 2695 T.

16. The method of claim 1, wherein the subject having an increased susceptibility for developing pulmonary hypertension is identified by detecting a BMPR2 nucleic acid having a sequence associated with pulmonary hypertension.

17. The method of claim 16, wherein the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension comprises a truncation mutation.

18. The method of claim 16, wherein the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension comprises a missense mutation.

19. The method of claim 16 wherein the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension comprises a nonsense mutation.

20. The method of claim 16, wherein the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension comprises a deletion mutation.

21. The method of claim 16, wherein the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension comprises a nucleic acid sequence having an insertion mutation.

22. The method of claim 16, wherein the BMPR2 nucleic acid having a sequence associated with pulmonary hypertension encodes a mutant BMPR-II polypeptide.

23. The method of claim 22, wherein the mutant BMPR-II polypeptide comprises at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2.

24. The method of claim 22, wherein the BMPR-II polypeptide comprises at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of 73, 118, 123, 143, 332, 348, 420, 485, 512, 519, and 899.

25. The method of claim 22, wherein the BMPR-II polypeptide comprises at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of a Trp residue at amino acid position 118, an Arg residue at amino acid position 123, a Ser residue at amino acid position 123, a Leu residue at amino acid position 143, an Ile residue at amino acid position 348, an Arg residue at amino acid position 420, an Ala residue at amino acid position 485, a Gln residue at amino acid position Gln, and a Lys residue at amino acid position 519.

26. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension terminates prematurely.

27. The method of claim 26, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension terminates at an amino acid position of the sequence set forth in SEQ ID NO:2 which is N-terminal to amino acid position 73, 332, or 899.

28. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one amino acid residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

29. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Cys residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

30. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid

substitution of at least one Pro residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

31. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Lys residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

32. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Arg residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

33. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Asp residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

34. The method of claim 22, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Glu residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

35. The method of claim 1, wherein the subject having an increased susceptibility for developing pulmonary hypertension is identified by detecting a mutant BMPR-II polypeptide in the subject.

36. The method of claim 35, wherein the mutant BMPR-II polypeptide terminates prematurely.

37. The method of claim 36, wherein the mutant BMPR-II polypeptide terminates at an amino acid position of the sequence set forth in SEQ ID NO:2 which is N-terminal to amino acid position 73, 332, or 899.

38. The method of claim 35, wherein the mutant BMPR-II polypeptide comprises a non-conservative substitution at an amino acid position.

39. The method of claim 38, wherein the mutant BMPR-II polypeptide comprises a non-conservative substitution for a Cys residue.

40. The method of claim 38, wherein the non-conservative substitution is selected from the group consisting of a Trp residue at amino acid position 118, an Arg residue at amino acid position 123, a Ser residue at amino acid position 123, a Leu residue at amino acid position 143, an Ile residue at amino acid position 348, an Arg residue at amino acid position 420, an Ala residue at amino acid position 485, a Gln residue at amino acid position Gln, and a Lys residue at amino acid position 519.

41. The method of claim 35, wherein the mutant BMPR-II polypeptide comprises an amino acid sequence that differs from the sequence set forth in SEQ ID NO:2.

42. The method of claim 41, wherein the mutant BMPR-II polypeptide comprises a mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of 73, 118, 123, 143, 332, 348, 420, 485, 512, 519, and 899.

43. The method of claim 35, wherein the BMPR-II polypeptide comprises at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of 73, 118, 123, 143, 332, 348, 420, 485, 512, 519, and 899.

44. The method of claim 35, wherein the BMPR-II polypeptide comprises at least one mutation at an amino acid position of the sequence set forth in SEQ ID NO:2 selected from the group consisting of a Trp residue at amino acid position 118, an Arg residue at amino acid position 123, a Ser residue at amino acid position 123, a Leu residue at amino acid position 143, an Ile residue at amino acid position 348, an Arg residue at amino acid position 420, an Ala residue at amino acid position 485, a Gln residue at amino acid position Gln, and a Lys residue at amino acid position 519.

45. The method of claim 1, wherein the subject having an increased susceptibility for developing pulmonary hypertension is identified by detecting a BMPR-II polypeptide having a sequence associated with pulmonary hypertension in the subject.

46. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension terminates prematurely.

47. The method of claim 46, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension terminates at an amino acid position of the sequence set forth in SEQ ID NO:2 which is N-terminal to amino acid position 73, 332, or 899.

48. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one amino acid residue of a BMPR-II having the amino acid sequence set forth in SEQ ID NO:2.

49. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Cys residue of a BMPR-II encoded by the nucleotide sequence set forth in SEQ ID NO:1.

50. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Pro residue of the wild-type BMPR-II encoded by the nucleotide sequence set forth in SEQ ID NO:1.

51. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Lys residue of the wild-type BMPR-II encoded by the nucleotide sequence set forth in SEQ ID NO:1.

52. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Arg residue of the wild-type BMPR-II encoded by the nucleotide sequence set forth in SEQ ID NO:1.

53. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid substitution of at least one Asp residue of the wild-type BMPR-II encoded by the nucleotide sequence set forth in SEQ ID NO:1.

54. The method of claim 45, wherein the BMPR-II polypeptide having a sequence associated with pulmonary hypertension has a non-conservative amino acid

substitution of at least one Glu residue of the wild-type BMPR-II encoded by the nucleotide sequence set forth in SEQ ID NO:1.

55. The method of claim 1, wherein the mutant BMPR-II polypeptide or mutated BMPR2 nucleic acid is due to a familial mutation.

56. The method of claim 1, wherein the mutant BMPR-II polypeptide or mutated BMPR2 nucleic acid is due to a sporadic mutation.


57. The method of claim 1, wherein the mutated BMPR2 nucleic acid has a sequence associated with pulmonary hypertension, wherein the mutated BMPR2 nucleic acid results in altered BMPR2 RNA function.

58. The method of claim 57, wherein the altered BMPR2 RNA function is reduced BMPR2 mRNA production, altered processing of BMPR2 RNA, or increased BMPR2 RNA instability.

59. The method of claim 58, wherein the altered BMPR2 RNA function is altered splicing of BMPR2 RNA.

60. A kit for identifying a subject having an increased susceptibility for developing pulmonary hypertension, comprising reagents for detecting a mutant Bone Morphogenic Protein Receptor II (BMPR-II) polypeptide or a mutated BMPR2 nucleic acid in the subject.

1/4



2/4





FIG. 1c



**FIG. 2**

4/4




FIG.3

## SEQUENCE LISTING

<110> Vanderbilt University  
 Children's Hospital Medical Center  
 Advanced Research & Technology Institute  
 University of Leicester

<120> METHOD OF DIAGNOSING PULMONARY  
 HYPERTENSION

<130> 22000.0108P1

<150> 60/218,740

<151> 2000-07-17

<150> 60/220,133

<151> 2000-07-21

<160> 36

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3122

<212> DNA

<213> Homo Sapiens

<221> CDS

<222> (1)...(3115)

<400> 1

atg	act	tcc	tcg	ctg	cag	cgg	ccc	tgg	cgg	gtg	ccc	tgg	cta	cca	tgg	48
Met	Thr	Ser	Ser	Leu	Gln	Arg	Pro	Trp	Arg	Val	Pro	Trp	Leu	Pro	Trp	
1				5				10					15			

acc	atc	ctg	ctg	gtc	agc	act	gcg	gct	gct	tcg	cag	aat	caa	gaa	cgg	96
Thr	Ile	Leu	Leu	Val	Ser	Thr	Ala	Ala	Ala	Ser	Gln	Asn	Gln	Glu	Arg	
			20					25					30			

cta	tgt	gcg	ttt	aaa	gat	ccg	tat	cag	caa	gac	ctt	ggg	ata	ggt	gag	144
Leu	Cys	Ala	Phe	Lys	Asp	Pro	Tyr	Gln	Gln	Asp	Leu	Gly	Ile	Gly	Glu	
		35					40					45				

agt	aga	atc	tct	cat	gaa	aat	ggg	aca	ata	tta	tgc	tcg	aaa	ggt	agc	192
Ser	Arg	Ile	Ser	His	Glu	Asn	Gly	Thr	Ile	Leu	Cys	Ser	Lys	Gly	Ser	
	50					55					60					

acc	tgc	tat	ggc	ctt	tgg	gag	aaa	tca	aaa	ggg	gac	ata	aat	ctt	gta	240
Thr	Cys	Tyr	Gly	Leu	Trp	Glu	Lys	Ser	Lys	Gly	Asp	Ile	Asn	Leu	Val	
	65				70					75					80	

aaa	caa	gga	tgt	tgg	tct	cac	att	gga	gat	ccc	caa	gag	tgt	cac	tat	288
Lys	Gln	Gly	Cys	Trp	Ser	His	Ile	Gly	Asp	Pro	Gln	Glu	Cys	His	Tyr	
			85						90					95		

gaa	gaa	tgt	gta	gta	act	acc	act	cct	ccc	tca	att	cag	aat	gga	aca	336
Glu	Glu	Cys	Val	Val	Thr	Thr	Thr	Pro	Pro	Ser	Ile	Gln	Asn	Gly	Thr	
			100					105						110		

tac cgt ttc tgc tgt tgt agc aca gat tta tgt aat gtc aac ttt act	384
Tyr Arg Phe Cys Cys Cys Ser Thr Asp Leu Cys Asn Val Asn Phe Thr	
115 120 125	
gag aat ttt cca cct cct gac aca aca cca ctc agt cca cct cat tca	432
Glu Asn Phe Pro Pro Pro Asp Thr Thr Pro Leu Ser Pro Pro His Ser	
130 135 140	
ttt aac cga gat gag aca ata atc att gct ttg gca tca gtc tct gta	480
Phe Asn Arg Asp Glu Thr Ile Ile Ile Ala Leu Ala Ser Val Ser Val	
145 150 155 160	
tta gct gtt ttg ata gtt gcc tta tgc ttt gga tac aga atg ttg aca	528
Leu Ala Val Leu Ile Val Ala Leu Cys Phe Gly Tyr Arg Met Leu Thr	
165 170 175	
gga gac cgt aaa caa ggt ctt cac agt atg aac atg atg gag gca gca	576
Gly Asp Arg Lys Gln Gly Leu His Ser Met Asn Met Met Glu Ala Ala	
180 185 190	
gca tcc gaa ccc tct ctt gat cta gat aat ctg aaa ctg ttg gag ctg	624
Ala Ser Glu Pro Ser Leu Asp Leu Asp Asn Leu Lys Leu Leu Glu Leu	
195 200 205	
att ggc cga ggt cga tat gga gca gta tat aaa ggc tcc ttg gat gag	672
Ile Gly Arg Gly Arg Tyr Gly Ala Val Tyr Lys Gly Ser Leu Asp Glu	
210 215 220	
cgt cca gtt gct gta aaa gtg ttt tcc ttt gca aac cgt cag aat ttt	720
Arg Pro Val Ala Val Lys Val Phe Ser Phe Ala Asn Arg Gln Asn Phe	
225 230 235 240	
atc aac gaa aag aac att tac aga gtg cct ttg atg gaa cat gac aac	768
Ile Asn Glu Lys Asn Ile Tyr Arg Val Pro Leu Met Glu His Asp Asn	
245 250 255	
att gcc cgc ttt ata gtt gga gat gag aga gtc act gca gat gga cgc	816
Ile Ala Arg Phe Ile Val Gly Asp Glu Arg Val Thr Ala Asp Gly Arg	
260 265 270	
atg gaa tat ttg ctt gtg atg gag tac tat ccc aat gga tct tta tgc	864
Met Glu Tyr Leu Leu Val Met Glu Tyr Tyr Pro Asn Gly Ser Leu Cys	
275 280 285	
aag tat tta agt ctc cac aca agt gac tgg gta agc tct tgc cgt ctt	912
Lys Tyr Leu Ser Leu His Thr Ser Asp Trp Val Ser Ser Cys Arg Leu	
290 295 300	
gct cat tct gtt act aga gga ctg gct tat ctt cac aca gaa tta cca	960
Ala His Ser Val Thr Arg Gly Leu Ala Tyr Leu His Thr Glu Leu Pro	
305 310 315 320	
cga gga gat cat tat aaa cct gca att tcc cat cga gat tta aac agc	1008
Arg Gly Asp His Tyr Lys Pro Ala Ile Ser His Arg Asp Leu Asn Ser	
325 330 335	
aga aat gtc cta gtg aaa aat gat gga acc tgt gtt att agt gac ttt	1056
Arg Asn Val Leu Val Lys Asn Asp Gly Thr Cys Val Ile Ser Asp Phe	
340 345 350	

gga ctg tcc atg agg ctg act gga aat aga ctg gtg cgc cca ggg gag	1104
Gly Leu Ser Met Arg Leu Thr Gly Asn Arg Leu Val Arg Pro Gly Glu	
355 360 365	
gaa gat aat gca gcc ata agc gag gtt ggc act atc aga tat atg gca	1152
Glu Asp Asn Ala Ala Ile Ser Glu Val Gly Thr Ile Arg Tyr Met Ala	
370 375 380	
cca gaa gtg cta gaa gga gct gtg aac ttg agg gac tgt gaa tca gct	1200
Pro Glu Val Leu Glu Gly Ala Val Asn Leu Arg Asp Cys Glu Ser Ala	
385 390 395 400	
ttg aaa caa gta gac atg tat gct ctt gga cta atc tat tgg gag ata	1248
Leu Lys Gln Val Asp Met Tyr Ala Leu Gly Leu Ile Tyr Trp Glu Ile	
405 410 415	
ttt atg aga tgt aca gac ctc ttc cca ggg gaa tcc gta cca gag tac	1296
Phe Met Arg Cys Thr Asp Leu Phe Pro Gly Glu Ser Val Pro Glu Tyr	
420 425 430	
cag atg gct ttt cag aca gag gtt gga aac cat ccc act ttt gag gat	1344
Gln Met Ala Phe Gln Thr Glu Val Gly Asn His Pro Thr Phe Glu Asp	
435 440 445	
atg cag gtt ctc gtg tct agg gaa aaa cag aga ccc aag ttc cca gaa	1392
Met Gln Val Leu Val Ser Arg Glu Lys Gln Arg Pro Lys Phe Pro Glu	
450 455 460	
gcc tgg aaa gaa aat agc ctg gca gtg agg tca ctc aag gag aca atc	1440
Ala Trp Lys Glu Asn Ser Leu Ala Val Arg Ser Leu Lys Glu Thr Ile	
465 470 475 480	
gaa gac tgt tgg gac cag gat gca gag gct cgg ctt act gca cag tgt	1488
Glu Asp Cys Trp Asp Gln Asp Ala Glu Ala Arg Leu Thr Ala Gln Cys	
485 490 495	
gct gag gaa agg atg gct gaa ctt atg atg att tgg gaa aga aac aaa	1536
Ala Glu Glu Arg Met Ala Glu Leu Met Met Ile Trp Glu Arg Asn Lys	
500 505 510	
tct gtg agc cca aca gtc aat cca atg tct act gct atg cag aat gaa	1584
Ser Val Ser Pro Thr Val Asn Pro Met Ser Thr Ala Met Gln Asn Glu	
515 520 525	
cgc aac ctg tca cat aat agg cgt gtg cca aaa att ggt cct tat cca	1632
Arg Asn Leu Ser His Asn Arg Arg Val Pro Lys Ile Gly Pro Tyr Pro	
530 535 540	
gat tat tct tcc tcc tca tac att gaa gac tct atc cat cat act gac	1680
Asp Tyr Ser Ser Ser Ser Tyr Ile Glu Asp Ser Ile His His Thr Asp	
545 550 555 560	
agc atc gtg aag aat att tcc tct gag cat tct atg tcc agc aca cct	1728
Ser Ile Val Lys Asn Ile Ser Ser Glu His Ser Met Ser Ser Thr Pro	
565 570 575	
ttg act ata ggg gaa aaa aac cga aat tca att aac tat gaa cga cag	1776
Leu Thr Ile Gly Glu Lys Asn Arg Asn Ser Ile Asn Tyr Glu Arg Gln	
580 585 590	

caa gca caa gct cga atc ccc agc cct gaa aca agt gtc acc agc ctc Gln Ala Gln Ala Arg Ile Pro Ser Pro Glu Thr Ser Val Thr Ser Leu 595 600 605	1824
tcc acc aac aca aca acc aca aac acc aca gga ctc acg cca agt act Ser Thr Asn Thr Thr Thr Thr Asn Thr Thr Gly Leu Thr Pro Ser Thr 610 615 620	1872
ggc atg act act ata tct gag atg cca tac cca gat gaa aca aat ctg Gly Met Thr Thr Ile Ser Glu Met Pro Tyr Pro Asp Glu Thr Asn Leu 625 630 635 640	1920
cat acc aca aat gtt gca cag tca att ggg cca acc cct gtc tgc tta His Thr Thr Asn Val Ala Gln Ser Ile Gly Pro Thr Pro Val Cys Leu 645 650 655	1968
cag ctg aca gaa gaa gac ttg gaa acc aac aag cta gac cca aaa gaa Gln Leu Thr Glu Glu Asp Leu Glu Thr Asn Lys Leu Asp Pro Lys Glu 660 665 670	2016
gtt gat aag aac ctc aag gaa agc tct gat gag aat ctc atg gag cac Val Asp Lys Asn Leu Lys Glu Ser Ser Asp Glu Asn Leu Met Glu His 675 680 685	2064
tct ctt aaa cag ttc agt ggc cca gac cca ctg agc agt act agt tct Ser Leu Lys Gln Phe Ser Gly Pro Asp Pro Leu Ser Ser Thr Ser Ser 690 695 700	2112
agc ttg ctt tac cca ctc ata aaa ctt gca gta gaa gca act gga cag Ser Leu Leu Tyr Pro Leu Ile Lys Leu Ala Val Glu Ala Thr Gly Gln 705 710 715 720	2160
cag gac ttc aca cag act gca aat ggc caa gca tgt ttg att cct gat Gln Asp Phe Thr Gln Thr Ala Asn Gly Gln Ala Cys Leu Ile Pro Asp 725 730 735	2208
gtt ctg cct act cag atc tat cct ctc ccc aag cag cag aac ctt ccc Val Leu Pro Thr Gln Ile Tyr Pro Leu Pro Lys Gln Gln Asn Leu Pro 740 745 750	2256
aag aga cct act agt ttg cct ttg aac acc aaa aat tca aca aaa gag Lys Arg Pro Thr Ser Leu Pro Leu Asn Thr Lys Asn Ser Thr Lys Glu 755 760 765	2304
ccc cgg cta aaa ttt ggc agc aag cac aaa tca aac ttg aaa caa gtc Pro Arg Leu Lys Phe Gly Ser Lys His Lys Ser Asn Leu Lys Gln Val 770 775 780	2352
gaa act gga gtt gcc aag atg aat aca atc aat gca gca gaa cct cat Glu Thr Gly Val Ala Lys Met Asn Thr Ile Asn Ala Ala Glu Pro His 785 790 795 800	2400
gtg gtg aca gtc acc atg aat ggt gtg gca ggt aga aac cac agt gtt Val Val Thr Val Thr Met Asn Gly Val Ala Gly Arg Asn His Ser Val 805 810 815	2448
aac tcc cat gct gcc aca acc caa tat gcc aat agg aca gta cta tct Asn Ser His Ala Ala Thr Thr Gln Tyr Ala Asn Arg Thr Val Leu Ser 820 825 830	2496

ggc caa aca acc aac ata gtg aca cat agg gcc caa gaa atg ttg cag Gly Gln Thr Thr Asn Ile Val Thr His Arg Ala Gln Glu Met Leu Gln 835 840 845	2544
aat cag ttt att ggt gag gac acc cgg ctg aat att aat tcc agt cct Asn Gln Phe Ile Gly Glu Asp Thr Arg Leu Asn Ile Asn Ser Ser Pro 850 855 860	2592
gat gag cat gag cct tta ctg aga cga gag caa caa gct ggc cat gat Asp Glu His Glu Pro Leu Leu Arg Arg Glu Gln Gln Ala Gly His Asp 865 870 875 880	2640
gaa ggt gtt ctg gat cgt ctt gtg gac agg agg gaa cgg cca cta gaa Glu Gly Val Leu Asp Arg Leu Val Asp Arg Glu Arg Pro Leu Glu 885 890 895	2688
ggt ggc cga act aat tcc aat aac aac aac agc aat cca tgt tca gaa Gly Gly Arg Thr Asn Ser Asn Asn Asn Asn Ser Asn Pro Cys Ser Glu 900 905 910	2736
caa gat gtt ctt gca cag ggt gtt cca agc aca gca gca gat cct ggg Gln Asp Val Leu Ala Gln Gly Val Pro Ser Thr Ala Ala Asp Pro Gly 915 920 925	2784
cca tca aag ccc aga aga gca cag agg cct aat tct ctg gat ctt tca Pro Ser Lys Pro Arg Arg Gln Gln Arg Pro Asn Ser Leu Asp Leu Ser 930 935 940	2832
gcc aca aat gtc ctg gat ggc agc agt ata cag ata ggt gag tca aca Ala Thr Asn Val Leu Asp Gly Ser Ser Ile Gln Ile Gly Glu Ser Thr 945 950 955 960	2880
caa gat ggc aaa tca gga tca ggt gaa aag atc aag aaa cgt gtg aaa Gln Asp Gly Lys Ser Gly Ser Gly Glu Lys Ile Lys Lys Arg Val Lys 965 970 975	2928
act ccc tat tct ctt aag cgg tgg cgc ccc tcc acc tgg gtc atc tcc Thr Pro Tyr Ser Leu Lys Arg Trp Arg Pro Ser Thr Trp Val Ile Ser 980 985 990	2976
act gaa tcg ctg gac tgt gaa gtc aac aat aat ggc agt aac agg gca Thr Glu Ser Leu Asp Cys Glu Val Asn Asn Asn Gly Ser Asn Arg Ala 995 1000 1005	3024
gtt cat tcc aaa tcc agc act gct gtt tac ctt gca gaa gga ggc act Val His Ser Lys Ser Ser Thr Ala Val Tyr Leu Ala Glu Gly Gly Thr 1010 1015 1020	3072
gct aca acc atg gtg tct aaa gat ata gga atg aac tgt ctg t Ala Thr Thr Met Val Ser Lys Asp Ile Gly Met Asn Cys Leu 1025 1030 1035	3115
gaaatgt	3122
<210> 2	
<211> 1038	
<212> PRT	
<213> Homo Sapiens	
<400> 2	

Met	Thr	Ser	Ser	Leu	Gln	Arg	Pro	Trp	Arg	Val	Pro	Trp	Leu	Pro	Trp			
1				5					10					15				
Thr	Ile	Leu	Leu	Val	Ser	Thr	Ala	Ala	Ala	Ser	Gln	Asn	Gln	Glu	Arg			
			20					25					30					
Leu	Cys	Ala	Phe	Lys	Asp	Pro	Tyr	Gln	Gln	Asp	Leu	Gly	Ile	Gly	Glu			
		35					40					45						
Ser	Arg	Ile	Ser	His	Glu	Asn	Gly	Thr	Ile	Leu	Cys	Ser	Lys	Gly	Ser			
		50				55					60							
Thr	Cys	Tyr	Gly	Leu	Trp	Glu	Lys	Ser	Lys	Gly	Asp	Ile	Asn	Leu	Val			
65					70					75					80			
Lys	Gln	Gly	Cys	Trp	Ser	His	Ile	Gly	Asp	Pro	Gln	Glu	Cys	His	Tyr			
				85					90					95				
Glu	Glu	Cys	Val	Val	Thr	Thr	Thr	Pro	Pro	Ser	Ile	Gln	Asn	Gly	Thr			
			100					105					110					
Tyr	Arg	Phe	Cys	Cys	Cys	Ser	Thr	Asp	Leu	Cys	Asn	Val	Asn	Phe	Thr			
		115					120					125						
Glu	Asn	Phe	Pro	Pro	Pro	Asp	Thr	Thr	Pro	Leu	Ser	Pro	Pro	His	Ser			
		130				135					140							
Phe	Asn	Arg	Asp	Glu	Thr	Ile	Ile	Ile	Ala	Leu	Ala	Ser	Val	Ser	Val			
145					150					155					160			
Leu	Ala	Val	Leu	Ile	Val	Ala	Leu	Cys	Phe	Gly	Tyr	Arg	Met	Leu	Thr			
				165					170					175				
Gly	Asp	Arg	Lys	Gln	Gly	Leu	His	Ser	Met	Asn	Met	Met	Glu	Ala	Ala			
			180					185					190					
Ala	Ser	Glu	Pro	Ser	Leu	Asp	Leu	Asp	Asn	Leu	Lys	Leu	Leu	Glu	Leu			
		195					200					205						
Ile	Gly	Arg	Gly	Arg	Tyr	Gly	Ala	Val	Tyr	Lys	Gly	Ser	Leu	Asp	Glu			
	210					215					220							
Arg	Pro	Val	Ala	Val	Lys	Val	Phe	Ser	Phe	Ala	Asn	Arg	Gln	Asn	Phe			
225					230					235					240			
Ile	Asn	Glu	Lys	Asn	Ile	Tyr	Arg	Val	Pro	Leu	Met	Glu	His	Asp	Asn			
				245					250					255				
Ile	Ala	Arg	Phe	Ile	Val	Gly	Asp	Glu	Arg	Val	Thr	Ala	Asp	Gly	Arg			
			260					265					270					
Met	Glu	Tyr	Leu	Leu	Val	Met	Glu	Tyr	Tyr	Pro	Asn	Gly	Ser	Leu	Cys			
		275					280					285						
Lys	Tyr	Leu	Ser	Leu	His	Thr	Ser	Asp	Trp	Val	Ser	Ser	Cys	Arg	Leu			
		290				295					300							
Ala	His	Ser	Val	Thr	Arg	Gly	Leu	Ala	Tyr	Leu	His	Thr	Glu	Leu	Pro			
305					310					315					320			
Arg	Gly	Asp	His	Tyr	Lys	Pro	Ala	Ile	Ser	His	Arg	Asp	Leu	Asn	Ser			
				325					330					335				
Arg	Asn	Val	Leu	Val	Lys	Asn	Asp	Gly	Thr	Cys	Val	Ile	Ser	Asp	Phe			
			340					345					350					
Gly	Leu	Ser	Met	Arg	Leu	Thr	Gly	Asn	Arg	Leu	Val	Arg	Pro	Gly	Glu			
		355					360					365						
Glu	Asp	Asn	Ala	Ala	Ile	Ser	Glu	Val	Gly	Thr	Ile	Arg	Tyr	Met	Ala			
		370				375					380							
Pro	Glu	Val	Leu	Glu	Gly	Ala	Val	Asn	Leu	Arg	Asp	Cys	Glu	Ser	Ala			
385					390					395					400			
Leu	Lys	Gln	Val	Asp	Met	Tyr	Ala	Leu	Gly	Leu	Ile	Tyr	Trp	Glu	Ile			
				405					410					415				
Phe	Met	Arg	Cys	Thr	Asp	Leu	Phe	Pro	Gly	Glu	Ser	Val	Pro	Glu	Tyr			
			420					425					430					
Gln	Met	Ala	Phe	Gln	Thr	Glu	Val	Gly	Asn	His	Pro	Thr	Phe	Glu	Asp			
		435					440					445						
Met	Gln	Val	Leu	Val	Ser	Arg	Glu	Lys	Gln	Arg	Pro	Lys	Phe	Pro	Glu			
		450				455					460							
Ala	Trp	Lys	Glu	Asn	Ser	Leu	Ala	Val	Arg	Ser	Leu	Lys	Glu	Thr	Ile			
465					470					475					480			

Glu	Asp	Cys	Trp	Asp	Gln	Asp	Ala	Glu	Ala	Arg	Leu	Thr	Ala	Gln	Cys
				485					490					495	
Ala	Glu	Glu	Arg	Met	Ala	Glu	Leu	Met	Met	Ile	Trp	Glu	Arg	Asn	Lys
			500					505						510	
Ser	Val	Ser	Pro	Thr	Val	Asn	Pro	Met	Ser	Thr	Ala	Met	Gln	Asn	Glu
			515				520					525			
Arg	Asn	Leu	Ser	His	Asn	Arg	Arg	Val	Pro	Lys	Ile	Gly	Pro	Tyr	Pro
			530			535					540				
Asp	Tyr	Ser	Ser	Ser	Ser	Tyr	Ile	Glu	Asp	Ser	Ile	His	His	Thr	Asp
545						550				555					560
Ser	Ile	Val	Lys	Asn	Ile	Ser	Ser	Glu	His	Ser	Met	Ser	Ser	Thr	Pro
				565					570					575	
Leu	Thr	Ile	Gly	Glu	Lys	Asn	Arg	Asn	Ser	Ile	Asn	Tyr	Glu	Arg	Gln
			580					585					590		
Gln	Ala	Gln	Ala	Arg	Ile	Pro	Ser	Pro	Glu	Thr	Ser	Val	Thr	Ser	Leu
			595				600					605			
Ser	Thr	Asn	Thr	Thr	Thr	Thr	Asn	Thr	Thr	Gly	Leu	Thr	Pro	Ser	Thr
			610			615					620				
Gly	Met	Thr	Thr	Ile	Ser	Glu	Met	Pro	Tyr	Pro	Asp	Glu	Thr	Asn	Leu
625					630					635					640
His	Thr	Thr	Asn	Val	Ala	Gln	Ser	Ile	Gly	Pro	Thr	Pro	Val	Cys	Leu
				645					650					655	
Gln	Leu	Thr	Glu	Glu	Asp	Leu	Glu	Thr	Asn	Lys	Leu	Asp	Pro	Lys	Glu
			660					665					670		
Val	Asp	Lys	Asn	Leu	Lys	Glu	Ser	Ser	Asp	Glu	Asn	Leu	Met	Glu	His
			675				680					685			
Ser	Leu	Lys	Gln	Phe	Ser	Gly	Pro	Asp	Pro	Leu	Ser	Ser	Thr	Ser	Ser
			690			695					700				
Ser	Leu	Leu	Tyr	Pro	Leu	Ile	Lys	Leu	Ala	Val	Glu	Ala	Thr	Gly	Gln
705					710					715					720
Gln	Asp	Phe	Thr	Gln	Thr	Ala	Asn	Gly	Gln	Ala	Cys	Leu	Ile	Pro	Asp
				725				730						735	
Val	Leu	Pro	Thr	Gln	Ile	Tyr	Pro	Leu	Pro	Lys	Gln	Gln	Asn	Leu	Pro
			740				745						750		
Lys	Arg	Pro	Thr	Ser	Leu	Pro	Leu	Asn	Thr	Lys	Asn	Ser	Thr	Lys	Glu
			755				760					765			
Pro	Arg	Leu	Lys	Phe	Gly	Ser	Lys	His	Lys	Ser	Asn	Leu	Lys	Gln	Val
			770			775					780				
Glu	Thr	Gly	Val	Ala	Lys	Met	Asn	Thr	Ile	Asn	Ala	Ala	Glu	Pro	His
785					790					795					800
Val	Val	Thr	Val	Thr	Met	Asn	Gly	Val	Ala	Gly	Arg	Asn	His	Ser	Val
				805				810						815	
Asn	Ser	His	Ala	Ala	Thr	Thr	Gln	Tyr	Ala	Asn	Arg	Thr	Val	Leu	Ser
			820				825						830		
Gly	Gln	Thr	Thr	Asn	Ile	Val	Thr	His	Arg	Ala	Gln	Glu	Met	Leu	Gln
			835				840					845			
Asn	Gln	Phe	Ile	Gly	Glu	Asp	Thr	Arg	Leu	Asn	Ile	Asn	Ser	Ser	Pro
						855					860				
Asp	Glu	His	Glu	Pro	Leu	Leu	Arg	Arg	Glu	Gln	Gln	Ala	Gly	His	Asp
865					870					875					880
Glu	Gly	Val	Leu	Asp	Arg	Leu	Val	Asp	Arg	Glu	Arg	Pro	Leu	Glu	
				885				890						895	
Gly	Gly	Arg	Thr	Asn	Ser	Asn	Asn	Asn	Asn	Ser	Asn	Pro	Cys	Ser	Glu
			900					905					910		
Gln	Asp	Val	Leu	Ala	Gln	Gly	Val	Pro	Ser	Thr	Ala	Ala	Asp	Pro	Gly
			915				920					925			
Pro	Ser	Lys	Pro	Arg	Arg	Ala	Gln	Arg	Pro	Asn	Ser	Leu	Asp	Leu	Ser
						935					940				
Ala	Thr	Asn	Val	Leu	Asp	Gly	Ser	Ser	Ile	Gln	Ile	Gly	Glu	Ser	Thr
945					950					955					960

Gln Asp Gly Lys Ser Gly Ser Gly Glu Lys Ile Lys Lys Arg Val Lys  
                                   965                                  970                                  975  
 Thr Pro Tyr Ser Leu Lys Arg Trp Arg Pro Ser Thr Trp Val Ile Ser  
                                   980                                  985                                  990  
 Thr Glu Ser Leu Asp Cys Glu Val Asn Asn Asn Gly Ser Asn Arg Ala  
                                   995                                  1000                                  1005  
 Val His Ser Lys Ser Ser Thr Ala Val Tyr Leu Ala Glu Gly Gly Thr  
                                   1010                                  1015                                  1020  
 Ala Thr Thr Met Val Ser Lys Asp Ile Gly Met Asn Cys Leu  
                                   1025                                  1030                                  1035

<210> 3  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence; Note =  
       Synthetic Construct

<400> 3  
 agctaggtcc tctcatcagc

20

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence; Note =  
       Synthetic Construct

<400> 4  
 cagccgcagt gctgaccagc

20

<210> 5  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence; Note =  
       Synthetic Construct

<400> 5  
 gtcattcgga taagacaaag

20

<210> 6  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence; Note =  
       Synthetic Construct

<400> 6  
 tttaacatac tcccatgtcc

20

<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 7  
tagcttacac gtactctcac 20

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 8  
cctggcttca accttgaatg 20

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 9  
gggtacagcc tttctaaagg 20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 10  
gatactattg aggctgggtg 20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 11  
gctgctaatac tttctgcagc 20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 12  
gaatgaagtc actgttccag 20

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 13  
cagagagctg tagcattctg 20

<210> 14  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 14  
aagtgatcca cctgccttag 20

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 15  
actcttcacg ttaaagtgag 20

<210> 16  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 16  
ctttgaagat ataattaaaa tttcc 25

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 17  
cacctggcca gtagatgttt 20

<210> 18  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 18  
tgttcaatag tcccttttat tcattg 26

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 19  
ctaatttgca tcctgctgct 20

<210> 20  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 20  
tgttcttcag aatatgctac gttctc 26

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 21  
ttgtggcatt aggcaactcc 20

<210> 22  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 22  
gcctgaaggg gatgaaaaa

19

<210> 23  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 23  
ccacaccct taggtctta

20

<210> 24  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 24  
cacatgggtt gacatgtact ttg

23

<210> 25  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 25  
catcagagct ttccttgagg tt

22

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 26  
cagaggtgtt aaatttgagg

20

<210> 27  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 27  
tctacctgcc acaccattca 20

<210> 28  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 28  
tggaacacaa caagctagac c 21

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 29  
ccccaaaaga cacacaggag 20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 30  
tgaatggtgt ggcaggtaga 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 31  
gctgacagga ggataaagca 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 32  
caccctcctg agacattggt 20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 33  
accaaatatg ccaatgggac 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 34  
ttcgccacct tctagtggt 20

<210> 35  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 35  
catgtggtaa actgaaaagc tca 23

<210> 36  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence; Note =  
Synthetic Construct

<400> 36  
ttgagaccac tttgatacac aca 23